1
|
Delgado J, Pritchard W, Varble N, Mikhail A, Owen J, Arrichiello A, Ray T, Lopez-Silva T, Morhard R, Yang J, Kassin M, Mueller J, Xu S, Schneider J, Karanian J, Wood B. Abstract No. 242 Distribution of Imageable Thermosensitive Drug-Loaded Gel in Ex Vivo Bovine Liver Depends on Needle Type and Injection Technique. J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
|
2
|
Abe H, Abe S, Acciari VA, Aniello T, Ansoldi S, Antonelli LA, Arbet Engels A, Arcaro C, Artero M, Asano K, Baack D, Babić A, Baquero A, Barres de Almeida U, Barrio JA, Batković I, Baxter J, Becerra González J, Bednarek W, Bernardini E, Bernardos M, Berti A, Besenrieder J, Bhattacharyya W, Bigongiari C, Biland A, Blanch O, Bonnoli G, Bošnjak Ž, Burelli I, Busetto G, Carosi R, Carretero-Castrillo M, Ceribella G, Chai Y, Chilingarian A, Cikota S, Colombo E, Contreras JL, Cortina J, Covino S, D'Amico G, D'Elia V, Da Vela P, Dazzi F, De Angelis A, De Lotto B, Del Popolo A, Delfino M, Delgado J, Delgado Mendez C, Depaoli D, Di Pierro F, Di Venere L, Do Souto Espiñeira E, Dominis Prester D, Donini A, Dorner D, Doro M, Elsaesser D, Emery G, Fallah Ramazani V, Fariña L, Fattorini A, Font L, Fruck C, Fukami S, Fukazawa Y, García López RJ, Garczarczyk M, Gasparyan S, Gaug M, Giesbrecht Paiva JG, Giglietto N, Giordano F, Gliwny P, Godinović N, Green JG, Green D, Hadasch D, Hahn A, Hassan T, Heckmann L, Herrera J, Hrupec D, Hütten M, Imazawa R, Inada T, Iotov R, Ishio K, Jiménez Martínez I, Jormanainen J, Kerszberg D, Kobayashi Y, Kubo H, Kushida J, Lamastra A, Lelas D, Leone F, Lindfors E, Linhoff L, Lombardi S, Longo F, López-Coto R, López-Moya M, López-Oramas A, Loporchio S, Lorini A, Lyard E, Machado de Oliveira Fraga B, Majumdar P, Makariev M, Maneva G, Mang N, Manganaro M, Mangano S, Mannheim K, Mariotti M, Martínez M, Mas Aguilar A, Mazin D, Menchiari S, Mender S, Mićanović S, Miceli D, Miener T, Miranda JM, Mirzoyan R, Molina E, Mondal HA, Moralejo A, Morcuende D, Moreno V, Nakamori T, Nanci C, Nava L, Neustroev V, Nievas Rosillo M, Nigro C, Nilsson K, Nishijima K, Njoh Ekoume T, Noda K, Nozaki S, Ohtani Y, Oka T, Otero-Santos J, Paiano S, Palatiello M, Paneque D, Paoletti R, Paredes JM, Pavletić L, Persic M, Pihet M, Podobnik F, Prada Moroni PG, Prandini E, Principe G, Priyadarshi C, Puljak I, Rhode W, Ribó M, Rico J, Righi C, Rugliancich A, Sahakyan N, Saito T, Sakurai S, Satalecka K, Saturni FG, Schleicher B, Schmidt K, Schmuckermaier F, Schubert JL, Schweizer T, Sitarek J, Sliusar V, Sobczynska D, Spolon A, Stamerra A, Strišković J, Strom D, Strzys M, Suda Y, Surić T, Takahashi M, Takeishi R, Tavecchio F, Temnikov P, Terauchi K, Terzić T, Teshima M, Tosti L, Truzzi S, Tutone A, Ubach S, van Scherpenberg J, Vazquez Acosta M, Ventura S, Verguilov V, Viale I, Vigorito CF, Vitale V, Vovk I, Walter R, Will M, Wunderlich C, Yamamoto T, Zarić D, Hiroshima N, Kohri K. Search for Gamma-Ray Spectral Lines from Dark Matter Annihilation up to 100 TeV toward the Galactic Center with MAGIC. Phys Rev Lett 2023; 130:061002. [PMID: 36827578 DOI: 10.1103/physrevlett.130.061002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 11/02/2022] [Accepted: 12/15/2022] [Indexed: 06/18/2023]
Abstract
Linelike features in TeV γ rays constitute a "smoking gun" for TeV-scale particle dark matter and new physics. Probing the Galactic Center region with ground-based Cherenkov telescopes enables the search for TeV spectral features in immediate association with a dense dark matter reservoir at a sensitivity out of reach for satellite γ-ray detectors, and direct detection and collider experiments. We report on 223 hours of observations of the Galactic Center region with the MAGIC stereoscopic telescope system reaching γ-ray energies up to 100 TeV. We improved the sensitivity to spectral lines at high energies using large-zenith-angle observations and a novel background modeling method within a maximum-likelihood analysis in the energy domain. No linelike spectral feature is found in our analysis. Therefore, we constrain the cross section for dark matter annihilation into two photons to ⟨σv⟩≲5×10^{-28} cm^{3} s^{-1} at 1 TeV and ⟨σv⟩≲1×10^{-25} cm^{3} s^{-1} at 100 TeV, achieving the best limits to date for a dark matter mass above 20 TeV and a cuspy dark matter profile at the Galactic Center. Finally, we use the derived limits for both cuspy and cored dark matter profiles to constrain supersymmetric wino models.
Collapse
Affiliation(s)
- H Abe
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - S Abe
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - V A Acciari
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - T Aniello
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - S Ansoldi
- Università di Udine and INFN Trieste, I-33100 Udine, Italy
| | - L A Antonelli
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - A Arbet Engels
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - C Arcaro
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M Artero
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - K Asano
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - D Baack
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - A Babić
- Croatian MAGIC Group: University of Zagreb, Faculty of Electrical Engineering and Computing (FER), 10000 Zagreb, Croatia
| | - A Baquero
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - U Barres de Almeida
- Centro Brasileiro de Pesquisas Físicas (CBPF), 22290-180 URCA, Rio de Janeiro (RJ), Brazil
| | - J A Barrio
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - I Batković
- Università di Padova and INFN, I-35131 Padova, Italy
| | - J Baxter
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - J Becerra González
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - W Bednarek
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - E Bernardini
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M Bernardos
- Instituto de Astrofísica de Andalucía-CSIC, Glorieta de la Astronomía s/n, 18008 Granada, Spain
| | - A Berti
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - J Besenrieder
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - W Bhattacharyya
- Deutsches Elektronen-Synchrotron (DESY), D-15738 Zeuthen, Germany
| | - C Bigongiari
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - A Biland
- ETH Zürich, CH-8093 Zürich, Switzerland
| | - O Blanch
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - G Bonnoli
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - Ž Bošnjak
- Croatian MAGIC Group: University of Zagreb, Faculty of Electrical Engineering and Computing (FER), 10000 Zagreb, Croatia
| | - I Burelli
- Università di Udine and INFN Trieste, I-33100 Udine, Italy
| | - G Busetto
- Università di Padova and INFN, I-35131 Padova, Italy
| | - R Carosi
- Università di Pisa and INFN Pisa, I-56126 Pisa, Italy
| | | | - G Ceribella
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - Y Chai
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - A Chilingarian
- Armenian MAGIC Group: A. Alikhanyan National Science Laboratory, 0036 Yerevan, Armenia
| | - S Cikota
- Croatian MAGIC Group: University of Zagreb, Faculty of Electrical Engineering and Computing (FER), 10000 Zagreb, Croatia
| | - E Colombo
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - J L Contreras
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - J Cortina
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, E-28040 Madrid, Spain
| | - S Covino
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - G D'Amico
- Department for Physics and Technology, University of Bergen, Norway
| | - V D'Elia
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - P Da Vela
- Università di Pisa and INFN Pisa, I-56126 Pisa, Italy
| | - F Dazzi
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - A De Angelis
- Università di Padova and INFN, I-35131 Padova, Italy
| | - B De Lotto
- Università di Udine and INFN Trieste, I-33100 Udine, Italy
| | - A Del Popolo
- INFN MAGIC Group: INFN Sezione di Catania and Dipartimento di Fisica e Astronomia, University of Catania, I-95123 Catania, Italy
| | - M Delfino
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - J Delgado
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - C Delgado Mendez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, E-28040 Madrid, Spain
| | - D Depaoli
- INFN MAGIC Group: INFN Sezione di Torino and Università degli Studi di Torino, I-10125 Torino, Italy
| | - F Di Pierro
- INFN MAGIC Group: INFN Sezione di Torino and Università degli Studi di Torino, I-10125 Torino, Italy
| | - L Di Venere
- INFN MAGIC Group: INFN Sezione di Bari and Dipartimento Interateneo di Fisica dell'Università e del Politecnico di Bari, I-70125 Bari, Italy
| | - E Do Souto Espiñeira
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - D Dominis Prester
- Croatian MAGIC Group: University of Rijeka, Department of Physics, 51000 Rijeka, Croatia
| | - A Donini
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - D Dorner
- Universität Würzburg, D-97074 Würzburg, Germany
| | - M Doro
- Università di Padova and INFN, I-35131 Padova, Italy
| | - D Elsaesser
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - G Emery
- University of Geneva, Chemin d'Ecogia 16, CH-1290 Versoix, Switzerland
| | - V Fallah Ramazani
- Finnish MAGIC Group: Finnish Centre for Astronomy with ESO, University of Turku, FI-20014 Turku, Finland
| | - L Fariña
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - A Fattorini
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - L Font
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - C Fruck
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - S Fukami
- ETH Zürich, CH-8093 Zürich, Switzerland
| | - Y Fukazawa
- Japanese MAGIC Group: Physics Program, Graduate School of Advanced Science and Engineering, Hiroshima University, 739-8526 Hiroshima, Japan
| | - R J García López
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - M Garczarczyk
- Deutsches Elektronen-Synchrotron (DESY), D-15738 Zeuthen, Germany
| | - S Gasparyan
- Armenian MAGIC Group: ICRANet-Armenia at NAS RA, 0019 Yerevan, Armenia
| | - M Gaug
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - J G Giesbrecht Paiva
- Centro Brasileiro de Pesquisas Físicas (CBPF), 22290-180 URCA, Rio de Janeiro (RJ), Brazil
| | - N Giglietto
- INFN MAGIC Group: INFN Sezione di Bari and Dipartimento Interateneo di Fisica dell'Università e del Politecnico di Bari, I-70125 Bari, Italy
| | - F Giordano
- INFN MAGIC Group: INFN Sezione di Bari and Dipartimento Interateneo di Fisica dell'Università e del Politecnico di Bari, I-70125 Bari, Italy
| | - P Gliwny
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - N Godinović
- Croatian MAGIC Group: University of Split, Faculty of Electrical Engineering, Mechanical Engineering and Naval Architecture (FESB), 21000 Split, Croatia
| | - J G Green
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - D Green
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - D Hadasch
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - A Hahn
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - T Hassan
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, E-28040 Madrid, Spain
| | - L Heckmann
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - J Herrera
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - D Hrupec
- Croatian MAGIC Group: Josip Juraj Strossmayer University of Osijek, Department of Physics, 31000 Osijek, Croatia
| | - M Hütten
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - R Imazawa
- Japanese MAGIC Group: Physics Program, Graduate School of Advanced Science and Engineering, Hiroshima University, 739-8526 Hiroshima, Japan
| | - T Inada
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - R Iotov
- Universität Würzburg, D-97074 Würzburg, Germany
| | - K Ishio
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - I Jiménez Martínez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, E-28040 Madrid, Spain
| | - J Jormanainen
- Finnish MAGIC Group: Finnish Centre for Astronomy with ESO, University of Turku, FI-20014 Turku, Finland
| | - D Kerszberg
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - Y Kobayashi
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - H Kubo
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - J Kushida
- Japanese MAGIC Group: Department of Physics, Tokai University, Hiratsuka, 259-1292 Kanagawa, Japan
| | - A Lamastra
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - D Lelas
- Croatian MAGIC Group: University of Split, Faculty of Electrical Engineering, Mechanical Engineering and Naval Architecture (FESB), 21000 Split, Croatia
| | - F Leone
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - E Lindfors
- Finnish MAGIC Group: Finnish Centre for Astronomy with ESO, University of Turku, FI-20014 Turku, Finland
| | - L Linhoff
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - S Lombardi
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - F Longo
- Università di Udine and INFN Trieste, I-33100 Udine, Italy
| | - R López-Coto
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M López-Moya
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - A López-Oramas
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - S Loporchio
- INFN MAGIC Group: INFN Sezione di Bari and Dipartimento Interateneo di Fisica dell'Università e del Politecnico di Bari, I-70125 Bari, Italy
| | - A Lorini
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - E Lyard
- University of Geneva, Chemin d'Ecogia 16, CH-1290 Versoix, Switzerland
| | | | - P Majumdar
- Saha Institute of Nuclear Physics, A CI of Homi Bhabha National Institute, Kolkata 700064, West Bengal, India
| | - M Makariev
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - G Maneva
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - N Mang
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - M Manganaro
- Croatian MAGIC Group: University of Rijeka, Department of Physics, 51000 Rijeka, Croatia
| | - S Mangano
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, E-28040 Madrid, Spain
| | - K Mannheim
- Universität Würzburg, D-97074 Würzburg, Germany
| | - M Mariotti
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M Martínez
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - A Mas Aguilar
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - D Mazin
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - S Menchiari
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - S Mender
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - S Mićanović
- Croatian MAGIC Group: University of Rijeka, Department of Physics, 51000 Rijeka, Croatia
| | - D Miceli
- Università di Padova and INFN, I-35131 Padova, Italy
| | - T Miener
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - J M Miranda
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - R Mirzoyan
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - E Molina
- Universitat de Barcelona, ICCUB, IEEC-UB, E-08028 Barcelona, Spain
| | - H A Mondal
- Saha Institute of Nuclear Physics, A CI of Homi Bhabha National Institute, Kolkata 700064, West Bengal, India
| | - A Moralejo
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - D Morcuende
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - V Moreno
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - T Nakamori
- Japanese MAGIC Group: Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - C Nanci
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - L Nava
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - V Neustroev
- Finnish MAGIC Group: Space Physics and Astronomy Research Unit, University of Oulu, FI-90014 Oulu, Finland
| | - M Nievas Rosillo
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - C Nigro
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - K Nilsson
- Finnish MAGIC Group: Finnish Centre for Astronomy with ESO, University of Turku, FI-20014 Turku, Finland
| | - K Nishijima
- Japanese MAGIC Group: Department of Physics, Tokai University, Hiratsuka, 259-1292 Kanagawa, Japan
| | - T Njoh Ekoume
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - K Noda
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - S Nozaki
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - Y Ohtani
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - T Oka
- Japanese MAGIC Group: Department of Physics, Kyoto University, 606-8502 Kyoto, Japan
| | - J Otero-Santos
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - S Paiano
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - M Palatiello
- Università di Udine and INFN Trieste, I-33100 Udine, Italy
| | - D Paneque
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - R Paoletti
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - J M Paredes
- Universitat de Barcelona, ICCUB, IEEC-UB, E-08028 Barcelona, Spain
| | - L Pavletić
- Croatian MAGIC Group: University of Rijeka, Department of Physics, 51000 Rijeka, Croatia
| | - M Persic
- Università di Udine and INFN Trieste, I-33100 Udine, Italy
| | - M Pihet
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - F Podobnik
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | | | - E Prandini
- Università di Padova and INFN, I-35131 Padova, Italy
| | - G Principe
- Università di Udine and INFN Trieste, I-33100 Udine, Italy
| | - C Priyadarshi
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - I Puljak
- Croatian MAGIC Group: University of Split, Faculty of Electrical Engineering, Mechanical Engineering and Naval Architecture (FESB), 21000 Split, Croatia
| | - W Rhode
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - M Ribó
- Universitat de Barcelona, ICCUB, IEEC-UB, E-08028 Barcelona, Spain
| | - J Rico
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - C Righi
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - A Rugliancich
- Università di Pisa and INFN Pisa, I-56126 Pisa, Italy
| | - N Sahakyan
- Armenian MAGIC Group: ICRANet-Armenia at NAS RA, 0019 Yerevan, Armenia
| | - T Saito
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - S Sakurai
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - K Satalecka
- Finnish MAGIC Group: Finnish Centre for Astronomy with ESO, University of Turku, FI-20014 Turku, Finland
| | - F G Saturni
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | | | - K Schmidt
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | | | - J L Schubert
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - T Schweizer
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - J Sitarek
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - V Sliusar
- University of Geneva, Chemin d'Ecogia 16, CH-1290 Versoix, Switzerland
| | - D Sobczynska
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - A Spolon
- Università di Padova and INFN, I-35131 Padova, Italy
| | - A Stamerra
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - J Strišković
- Croatian MAGIC Group: Josip Juraj Strossmayer University of Osijek, Department of Physics, 31000 Osijek, Croatia
| | - D Strom
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - M Strzys
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - Y Suda
- Japanese MAGIC Group: Physics Program, Graduate School of Advanced Science and Engineering, Hiroshima University, 739-8526 Hiroshima, Japan
| | - T Surić
- Croatian MAGIC Group: Ruđer Bošković Institute, 10000 Zagreb, Croatia
| | - M Takahashi
- Japanese MAGIC Group: Institute for Space-Earth Environmental Research and Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, Nagoya University, 464-6801 Nagoya, Japan
| | - R Takeishi
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - F Tavecchio
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - P Temnikov
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - K Terauchi
- Japanese MAGIC Group: Department of Physics, Kyoto University, 606-8502 Kyoto, Japan
| | - T Terzić
- Croatian MAGIC Group: University of Rijeka, Department of Physics, 51000 Rijeka, Croatia
| | - M Teshima
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - L Tosti
- INFN MAGIC Group: INFN Sezione di Perugia, I-06123 Perugia, Italy
| | - S Truzzi
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - A Tutone
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - S Ubach
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | | | - M Vazquez Acosta
- Instituto de Astrofísica de Canarias and Departamento de Astrofísica, Universidad de La Laguna, E-38200 La Laguna, Tenerife, Spain
| | - S Ventura
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - V Verguilov
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - I Viale
- Università di Padova and INFN, I-35131 Padova, Italy
| | - C F Vigorito
- INFN MAGIC Group: INFN Sezione di Torino and Università degli Studi di Torino, I-10125 Torino, Italy
| | - V Vitale
- INFN MAGIC Group: INFN Roma Tor Vergata, I-00133 Roma, Italy
| | - I Vovk
- Japanese MAGIC Group: Institute for Cosmic Ray Research (ICRR), The University of Tokyo, Kashiwa, 277-8582 Chiba, Japan
| | - R Walter
- University of Geneva, Chemin d'Ecogia 16, CH-1290 Versoix, Switzerland
| | - M Will
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - C Wunderlich
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - T Yamamoto
- Japanese MAGIC Group: Department of Physics, Konan University, Kobe, Hyogo 658-8501, Japan
| | - D Zarić
- Croatian MAGIC Group: University of Split, Faculty of Electrical Engineering, Mechanical Engineering and Naval Architecture (FESB), 21000 Split, Croatia
| | - N Hiroshima
- Department of Physics, University of Toyama, 3190 Gofuku, Toyama 930-8555, Japan
- RIKEN iTHEMS, Wako, Saitama 351-0198, Japan
| | - K Kohri
- Theory Center, IPNS, KEK, Tsukuba, Ibaraki 305-0801, Japan
- The Graduate University for Advanced Studies (SOKENDAI), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
- Kavli IPMU (WPI), UTIAS, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| |
Collapse
|
3
|
Lobo LM, Masson W, Masson G, Molinero G, Lavalle Cobo A, Huerin M, Delgado J, Benincasa F, Losada P. Statins and influenza mortality: systematic review and meta-analysis. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Due to their anti-inflammatory properties, it has been suggested that the use of statins could influence the evolution of influenza virus infection.
Objective
To evaluate the effect of statin therapy on mortality from influenza.
Material and methods
A meta-analysis that included studies evaluating the use of statins in patients with influenza and reporting data on mortality, after searching the PubMed/MEDLINE, Embase, and Cochrane Controlled Trials databases, was performed. A random effects model was applied. The risk of bias was analyzed and a sensitivity analysis was performed.
Results
Eight studies (10 independent cohorts), which included a total of 2,390,730 patients, were identified and eligible for analysis. A total of 1,146,995 subjects analyzed received statins, while 1,243,735 subjects were part of the control group. Statin therapy was associated with lower mortality (OR: 0.66; 95% CI: 0.51–0.85). The sensitivity analysis showed that the results were robust.
Conclusions
Our data suggest that, in a population with influenza, the use of statins was associated with a significant reduction in mortality. These results must be confirmed in future clinical trials.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- L M Lobo
- Campo de Mayo Military Hospital , Buenos Aires , Argentina
| | - W Masson
- Italian Hospital , Caba , Argentina
| | - G Masson
- Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology , Caba , Argentina
| | - G Molinero
- Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology , Caba , Argentina
| | - A Lavalle Cobo
- Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology , Caba , Argentina
| | - M Huerin
- Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology , Caba , Argentina
| | - J Delgado
- Campo de Mayo Military Hospital , Buenos Aires , Argentina
| | - F Benincasa
- Campo de Mayo Military Hospital , Buenos Aires , Argentina
| | - P Losada
- Campo de Mayo Military Hospital , Buenos Aires , Argentina
| |
Collapse
|
4
|
Padilla P, Estévez M, Andrade MJ, Peña FJ, Delgado J. Proteomics reveal the protective effects of chlorogenic acid on Enterococcus faecium Q233 in a simulated pro-oxidant colonic environment. Food Res Int 2022; 157:111464. [PMID: 35761697 DOI: 10.1016/j.foodres.2022.111464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 05/29/2022] [Accepted: 06/01/2022] [Indexed: 11/26/2022]
Abstract
Certain phytochemicals have been found to promote the beneficial effects of probiotic bacteria although the molecular mechanisms of such interactions are poorly understood. The objective of the present study was to evaluate the impact of the exposure to 0.5 mM chlorogenic acid (CA) on the redox status and proteome of Enterococcus faecium isolated from cheese and challenged with 2.5 mM hydrogen peroxide (H2O2). The bacterium was incubated in anaerobic conditions for 48 h at 37 °C. CA exposure led to a more intense oxidative stress and accretion of bacterial protein carbonyls than those induced by H2O2. The oxidative damage to bacterial proteins was even more severe in the bacterium treated with both CA and H2O2, yet, such combination led to a strengthening of the antioxidant defenses, namely, a catalase-like activity. The proteomic study indicated that H2O2 caused a decrease in energy supply and the bacterium responded by reinforcing the membrane and wall structures and counteracting the redox and pH imbalance. CA stimulated the accretion of proteins related to translation and transcription regulators, and hydrolases. This phytochemical was able to counteract certain proteomic changes induced by H2O2 (i.e. increase of ATP binding cassete (ABC) transporter complex) and cause the increase of Rex, a redox-sensitive protein implicated in controlling metabolism and responses to oxidative stress. Although this protection should be confirmed under in vivo conditions, such effects point to benefits in animals or humans affected by disorders in which oxidative stress plays a major role.
Collapse
Affiliation(s)
- P Padilla
- Food Technology and Quality (TECAL), Institute of Meat and Meat Products (IPROCAR), University of Extremadura, Cáceres, Spain; Food Hygiene and Safety (HISEALI), Institute of Meat and Meat Products (IPROCAR), University of Extremadura, Cáceres, Spain
| | - M Estévez
- Food Technology and Quality (TECAL), Institute of Meat and Meat Products (IPROCAR), University of Extremadura, Cáceres, Spain.
| | - M J Andrade
- Food Hygiene and Safety (HISEALI), Institute of Meat and Meat Products (IPROCAR), University of Extremadura, Cáceres, Spain
| | - F J Peña
- Spermatology Laboratory, University of Extremadura, Cáceres, Spain
| | - J Delgado
- Food Hygiene and Safety (HISEALI), Institute of Meat and Meat Products (IPROCAR), University of Extremadura, Cáceres, Spain
| |
Collapse
|
5
|
Díaz-Velasco S, Delgado J, Peña FJ, Estévez M. Protein oxidation marker, α-amino adipic acid, impairs proteome of differentiated human enterocytes: Underlying toxicological mechanisms. Biochim Biophys Acta Proteins Proteom 2022; 1870:140797. [PMID: 35691541 DOI: 10.1016/j.bbapap.2022.140797] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 05/28/2022] [Accepted: 06/06/2022] [Indexed: 12/13/2022]
Abstract
Protein oxidation and oxidative stress are involved in a variety of health disorders such as colorectal adenomas, inflammatory bowel's disease, neurological disorders and aging, among others. In particular, the specific final oxidation product from lysine, the α-amino adipic acid (α-AA), has been found in processed meat products and emphasized as a reliable marker of type II diabetes and obesity. Currently, the underlying mechanisms of the biological impairments caused by α-AA are unknown. To elucidate the molecular basis of the toxicological effect of α-AA, differentiated human enterocytes were exposed to dietary concentrations of α-AA (200 μM) and analyzed by flow cytometry, protein oxidation and proteomics using a Nanoliquid Chromatography-Orbitrap MS/MS. Cell viability was significantly affected by α-AA (p < 0.05). The proteomic study revealed that α-AA was able to alter cell homeostasis through impairment of the Na+/K+-ATPase pump, energetic metabolism, and antioxidant response, among other biological processes. These results show the importance of dietary oxidized amino acids in intestinal cell physiology and open the door to further studies to reveal the impact of protein oxidation products in pathological conditions.
Collapse
Affiliation(s)
- S Díaz-Velasco
- Food Technology and Quality (TECAL), Institute of Meat and Meat Products (IPROCAR), Universidad de Extremadura, Cáceres, Spain
| | - J Delgado
- Food Hygiene and Safety (HISEALI), Institute of Meat and Meat Products (IPROCAR), Universidad de Extremadura, Cáceres, Spain
| | - F J Peña
- Spermatology Laboratory, Universidad de Extremadura, Cáceres, Spain
| | - Mario Estévez
- Food Technology and Quality (TECAL), Institute of Meat and Meat Products (IPROCAR), Universidad de Extremadura, Cáceres, Spain.
| |
Collapse
|
6
|
Delgado J, Owen J, Pritchard W, Mikhail A, Varble N, Morhard R, Ray T, Kassin M, Lopez-Silva T, Rivera J, Mueller J, Yang J, Schneider J, Xu S, Karanian J, Wood B. Abstract No. 552 Dual ultrasound/x-ray imageable thermosensitive gel for intratumoral drug delivery and vessel embolization. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
7
|
Morhard R, Mikhail A, Negussie A, Mauda-Havakuk M, Delgado J, Kassin M, Zhang J, Pastan I, Hassan R, Pritchard W, Karanian J, Wood B. Abstract No. 334 Drug distribution maps with CT after direct co-injection with contrast agent in ex vivo tissue. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
8
|
Delgado J, Pritchard W, Mikhail A, Varble N, Lopez-Silva T, Morhard R, Mauda-Havakuk M, Ray T, Owen J, Negussie A, Schneider J, Karanian J, Wood B. Abstract No. 551 Characterization of an x-ray-imageable gel for image-guided intra-tumoral drug injections. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
9
|
Delgado J, Ory J, Bitran J, Blachman Braun R, Nackeeran S, Ramasamy R. Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Localized Prostate Cancer. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.01.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C, Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, de Tejada BM, Marzolini C, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rudin C, Schöni-Affolter F, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Weber R, Yerly S, van der Valk M, Geerlings SE, Goorhuis A, Hovius JW, Lempkes B, Nellen FJB, van der Poll T, Prins JM, Reiss P, van Vugt M, Wiersinga WJ, Wit FWMN, van Duinen M, van Eden J, Hazenberg A, van Hes AMH, Rajamanoharan S, Robinson T, Taylor B, Brewer C, Mayr C, Schmidt W, Speidel A, Strohbach F, Arastéh K, Cordes C, Pijnappel FJJ, Stündel M, Claus J, Baumgarten A, Carganico A, Ingiliz P, Dupke S, Freiwald M, Rausch M, Moll A, Schleehauf D, Smalhout SY, Hintsche B, Klausen G, Jessen H, Jessen A, Köppe S, Kreckel P, Schranz D, Fischer K, Schulbin H, Speer M, Weijsenfeld AM, Glaunsinger T, Wicke T, Bieniek B, Hillenbrand H, Schlote F, Lauenroth-Mai E, Schuler C, Schürmann D, Wesselmann H, Brockmeyer N, Jurriaans S, Gehring P, Schmalöer D, Hower M, Spornraft-Ragaller P, Häussinger D, Reuter S, Esser S, Markus R, Kreft B, Berzow D, Back NKT, Christl A, Meyer A, Plettenberg A, Stoehr A, Graefe K, Lorenzen T, Adam A, Schewe K, Weitner L, Fenske S, Zaaijer HL, Hansen S, Stellbrink HJ, Wiemer D, Hertling S, Schmidt R, Arbter P, Claus B, Galle P, Jäger H, Jä Gel-Guedes E, Berkhout B, Postel N, Fröschl M, Spinner C, Bogner J, Salzberger B, Schölmerich J, Audebert F, Marquardt T, Schaffert A, Schnaitmann E, Cornelissen MTE, Trein A, Frietsch B, Müller M, Ulmer A, Detering-Hübner B, Kern P, Schubert F, Dehn G, Schreiber M, Güler C, Schinkel CJ, Gunsenheimer-Bartmeyer B, Schmidt D, Meixenberger K, Bannert N, Wolthers KC, Peters EJG, van Agtmael MA, Autar RS, Bomers M, Sigaloff KCE, Heitmuller M, Laan LM, Ang CW, van Houdt R, Jonges M, Kuijpers TW, Pajkrt D, Scherpbier HJ, de Boer C, van der Plas A, van den Berge M, Stegeman A, Baas S, Hage de Looff L, Buiting A, Reuwer A, Veenemans J, Wintermans B, Pronk MJH, Ammerlaan HSM, van den Bersselaar DNJ, de Munnik ES, Deiman B, Jansz AR, Scharnhorst V, Tjhie J, Wegdam MCA, van Eeden A, Nellen J, Brokking W, Elsenburg LJM, Nobel H, van Kasteren MEE, Berrevoets MAH, Brouwer AE, Adams A, van Erve R, de Kruijf-van de Wiel BAFM, Keelan-Phaf S, van de Ven B, van der Ven B, Buiting AGM, Murck JL, de Vries-Sluijs TEMS, Bax HI, van Gorp ECM, de Jong-Peltenburg NC, de Mendonç A Melo M, van Nood E, Nouwen JL, Rijnders BJA, Rokx C, Schurink CAM, Slobbe L, Verbon A, Bassant N, van Beek JEA, Vriesde M, van Zonneveld LM, de Groot J, Boucher CAB, Koopmans MPG, van Kampen JJA, Fraaij PLA, van Rossum AMC, Vermont CL, van der Knaap LC, Visser E, Branger J, Douma RA, Cents-Bosma AS, Duijf-van de Ven CJHM, Schippers EF, van Nieuwkoop C, van Ijperen JM, Geilings J, van der Hut G, van Burgel ND, Leyten EMS, Gelinck LBS, Mollema F, Davids-Veldhuis S, Tearno C, Wildenbeest GS, Heikens E, Groeneveld PHP, Bouwhuis JW, Lammers AJJ, Kraan S, van Hulzen AGW, Kruiper MSM, van der Bliek GL, Bor PCJ, Debast SB, Wagenvoort GHJ, Kroon FP, de Boer MGJ, Jolink H, Lambregts MMC, Roukens AHE, Scheper H, Dorama W, van Holten N, Claas ECJ, Wessels E, den Hollander JG, El Moussaoui R, Pogany K, Brouwer CJ, Smit JV, Struik-Kalkman D, van Niekerk T, Pontesilli O, Lowe SH, Oude Lashof AML, Posthouwer D, van Wolfswinkel ME, Ackens RP, Burgers K, Schippers J, Weijenberg-Maes B, van Loo IHM, Havenith TRA, van Vonderen MGA, Kampschreur LM, Faber S, Steeman-Bouma R, Al Moujahid A, Kootstra GJ, Delsing CE, van der Burg-van de Plas M, Scheiberlich L, Kortmann W, van Twillert G, Renckens R, Ruiter-Pronk D, van Truijen-Oud FA, Cohen Stuart JWT, Jansen ER, Hoogewerf M, Rozemeijer W, van der Reijden WA, Sinnige JC, Brinkman K, van den Berk GEL, Blok WL, Lettinga KD, de Regt M, Schouten WEM, Stalenhoef JE, Veenstra J, Vrouenraets SME, Blaauw H, Geerders GF, Kleene MJ, Kok M, Knapen M, van der Meché IB, Mulder-Seeleman E, Toonen AJM, Wijnands S, Wttewaal E, Kwa D, van Crevel R, van Aerde K, Dofferhoff ASM, Henriet SSV, Ter Hofstede HJM, Hoogerwerf J, Keuter M, Richel O, Albers M, Grintjes-Huisman KJT, de Haan M, Marneef M, Strik-Albers R, Rahamat-Langendoen J, Stelma FF, Burger D, Gisolf EH, Hassing RJ, Claassen M, Ter Beest G, van Bentum PHM, Langebeek N, Tiemessen R, Swanink CMA, van Lelyveld SFL, Soetekouw R, van der Prijt LMM, van der Swaluw J, Bermon N, van der Reijden WA, Jansen R, Herpers BL, Veenendaal D, Verhagen DWM, Lauw FN, van Broekhuizen MC, van Wijk M, Bierman WFW, Bakker M, Kleinnijenhuis J, Kloeze E, Middel A, Postma DF, Schölvinck EH, Stienstra Y, Verhage AR, Wouthuyzen-Bakker M, Boonstra A, de Groot-de Jonge H, van der Meulen PA, de Weerd DA, Niesters HGM, van Leer-Buter CC, Knoester M, Hoepelman AIM, Arends JE, Barth RE, Bruns AHW, Ellerbroek PM, Mudrikova T, Oosterheert JJ, Schadd EM, van Welzen BJ, Aarsman K, Griffioen-van Santen BMG, de Kroon I, van Berkel M, van Rooijen CSAM, Schuurman R, Verduyn-Lunel F, Wensing AMJ, Bont LJ, Geelen SPM, Loeffen YGT, Wolfs TFW, Nauta N, Rooijakkers EOW, Holtsema H, Voigt R, van de Wetering D, Alberto A, van der Meer I, Rosingh A, Halaby T, Zaheri S, Boyd AC, Bezemer DO, van Sighem AI, Smit C, Hillebregt M, de Jong A, Woudstra T, Bergsma D, Meijering R, van de Sande L, Rutkens T, van der Vliet S, de Groot L, van den Akker M, Bakker Y, El Berkaoui A, Bezemer M, Brétin N, Djoechro E, Groters M, Kruijne E, Lelivelt KJ, Lodewijk C, Lucas E, Munjishvili L, Paling F, Peeck B, Ree C, Regtop R, Ruijs Y, Schoorl M, Schnörr P, Scheigrond A, Tuijn E, Veenenberg L, Visser KM, Witte EC, Ruijs Y, Van Frankenhuijsen M, Allegre T, Makhloufi D, Livrozet JM, Chiarello P, Godinot M, Brunel-Dalmas F, Gibert S, Trepo C, Peyramond D, Miailhes P, Koffi J, Thoirain V, Brochier C, Baudry T, Pailhes S, Lafeuillade A, Philip G, Hittinger G, Assi A, Lambry V, Rosenthal E, Naqvi A, Dunais B, Cua E, Pradier C, Durant J, Joulie A, Quinsat D, Tempesta S, Ravaux I, Martin IP, Faucher O, Cloarec N, Champagne H, Pichancourt G, Morlat P, Pistone T, Bonnet F, Mercie P, Faure I, Hessamfar M, Malvy D, Lacoste D, Pertusa MC, Vandenhende MA, Bernard N, Paccalin F, Martell C, Roger-Schmelz J, Receveur MC, Duffau P, Dondia D, Ribeiro E, Caltado S, Neau D, Dupont M, Dutronc H, Dauchy F, Cazanave C, Vareil MO, Wirth G, Le Puil S, Pellegrin JL, Raymond I, Viallard JF, Chaigne de Lalande S, Garipuy D, Delobel P, Obadia M, Cuzin L, Alvarez M, Biezunski N, Porte L, Massip P, Debard A, Balsarin F, Lagarrigue M, Prevoteau du Clary F, Aquilina C, Reynes J, Baillat V, Merle C, Lemoing V, Atoui N, Makinson A, Jacquet JM, Psomas C, Tramoni C, Aumaitre H, Saada M, Medus M, Malet M, Eden A, Neuville S, Ferreyra M, Sotto A, Barbuat C, Rouanet I, Leureillard D, Mauboussin JM, Lechiche C, Donsesco R, Cabie A, Abel S, Pierre-Francois S, Batala AS, Cerland C, Rangom C, Theresine N, Hoen B, Lamaury I, Fabre I, Schepers K, Curlier E, Ouissa R, Gaud C, Ricaud C, Rodet R, Wartel G, Sautron C, Beck-Wirth G, Michel C, Beck C, Halna JM, Kowalczyk J, Benomar M, Drobacheff-Thiebaut C, Chirouze C, Faucher JF, Parcelier F, Foltzer A, Haffner-Mauvais C, Hustache Mathieu M, Proust A, Piroth L, Chavanet P, Duong M, Buisson M, Waldner A, Mahy S, Gohier S, Croisier D, May T, Delestan M, Andre M, Zadeh MM, Martinot M, Rosolen B, Pachart A, Martha B, Jeunet N, Rey D, Cheneau C, Partisani M, Priester M, Bernard-Henry C, Batard ML, Fischer P, Berger JL, Kmiec I, Robineau O, Huleux T, Ajana F, Alcaraz I, Allienne C, Baclet V, Meybeck A, Valette M, Viget N, Aissi E, Biekre R, Cornavin P, Merrien D, Seghezzi JC, Machado M, Diab G, Raffi F, Bonnet B, Allavena C, Grossi O, Reliquet V, Billaud E, Brunet C, Bouchez S, Morineau-Le Houssine P, Sauser F, Boutoille D, Besnier M, Hue H, Hall N, Brosseau D, Souala F, Michelet C, Tattevin P, Arvieux C, Revest M, Leroy H, Chapplain JM, Dupont M, Fily F, Patra-Delo S, Lefeuvre C, Bernard L, Bastides F, Nau P, Verdon R, de la Blanchardiere A, Martin A, Feret P, Geffray L, Daniel C, Rohan J, Fialaire P, Chennebault JM, Rabier V, Abgueguen P, Rehaiem S, Luycx O, Niault M, Moreau P, Poinsignon Y, Goussef M, Mouton-Rioux V, Houlbert D, Alvarez-Huve S, Barbe F, Haret S, Perre P, Leantez-Nainville S, Esnault JL, Guimard T, Suaud I, Girard JJ, Simonet V, Debab Y, Schmit JL, Jacomet C, Weinberck P, Genet C, Pinet P, Ducroix S, Durox H, Denes É, Abraham B, Gourdon F, Antoniotti O, Molina JM, Ferret S, Lascoux-Combe C, Lafaurie M, Colin de Verdiere N, Ponscarme D, De Castro N, Aslan A, Rozenbaum W, Pintado C, Clavel F, Taulera O, Gatey C, Munier AL, Gazaigne S, Penot P, Conort G, Lerolle N, Leplatois A, Balausine S, Delgado J, Timsit J, Tabet M, Gerard L, Girard PM, Picard O, Tredup J, Bollens D, Valin N, Campa P, Bottero J, Lefebvre B, Tourneur M, Fonquernie L, Wemmert C, Lagneau JL, Yazdanpanah Y, Phung B, Pinto A, Vallois D, Cabras O, Louni F, Pialoux G, Lyavanc T, Berrebi V, Chas J, Lenagat S, Rami A, Diemer M, Parrinello M, Depond A, Salmon D, Guillevin L, Tahi T, Belarbi L, Loulergue P, Zak Dit Zbar O, Launay O, Silbermann B, Leport C, Alagna L, Pietri MP, Simon A, Bonmarchand M, Amirat N, Pichon F, Kirstetter M, Katlama C, Valantin MA, Tubiana R, Caby F, Schneider L, Ktorza N, Calin R, Merlet A, Ben Abdallah S, Weiss L, Buisson M, Batisse D, Karmochine M, Pavie J, Minozzi C, Jayle D, Castel P, Derouineau J, Kousignan P, Eliazevitch M, Pierre I, Collias L, Viard JP, Gilquin J, Sobel A, Slama L, Ghosn J, Hadacek B, Thu-Huyn N, Nait-Ighil L, Cros A, Maignan A, Duvivier C, Consigny PH, Lanternier F, Shoai-Tehrani M, Touam F, Jerbi S, Bodard L, Jung C, Goujard C, Quertainmont Y, Duracinsky M, Segeral O, Blanc A, Peretti D, Cheret A, Chantalat C, Dulucq MJ, Levy Y, Lelievre JD, Lascaux AS, Dumont C, Boue F, Chambrin V, Abgrall S, Kansau I, Raho-Moussa M, De Truchis P, Dinh A, Davido B, Marigot D, Berthe H, Devidas A, Chevojon P, Chabrol A, Agher N, Lemercier Y, Chaix F, Turpault I, Bouchaud O, Honore P, Rouveix E, Reimann E, Belan AG, Godin Collet C, Souak S, Mortier E, Bloch M, Simonpoli AM, Manceron V, Cahitte I, Hiraux E, Lafon E, Cordonnier F, Zeng AF, Zucman D, Majerholc C, Bornarel D, Uludag A, Gellen-Dautremer J, Lefort A, Bazin C, Daneluzzi V, Gerbe J, Jeantils V, Coupard M, Patey O, Bantsimba J, Delllion S, Paz PC, Cazenave B, Richier L, Garrait V, Delacroix I, Elharrar B, Vittecoq D, Bolliot C, Lepretre A, Genet P, Masse V, Perrone V, Boussard JL, Chardon P, Froguel E, Simon P, Tassi S, Avettand Fenoel V, Barin F, Bourgeois C, Cardon F, Chaix ML, Delfraissy JF, Essat A, Fischer H, Lecuroux C, Meyer L, Petrov-Sanchez V, Rouzioux C, Saez-Cirion A, Seng R, Kuldanek K, Mullaney S, Young C, Zucchetti A, Bevan MA, McKernan S, Wandolo E, Richardson C, Youssef E, Green P, Faulkner S, Faville R, Herman S, Care C, Blackman H, Bellenger K, Fairbrother K, Phillips A, Babiker A, Delpech V, Fidler S, Clarke M, Fox J, Gilson R, Goldberg D, Hawkins D, Johnson A, Johnson M, McLean K, Nastouli E, Post F, Kennedy N, Pritchard J, Andrady U, Rajda N, Donnelly C, McKernan S, Drake S, Gilleran G, White D, Ross J, Harding J, Faville R, Sweeney J, Flegg P, Toomer S, Wilding H, Woodward R, Dean G, Richardson C, Perry N, Gompels M, Jennings L, Bansaal D, Browing M, Connolly L, Stanley B, Estreich S, Magdy A, O'Mahony C, Fraser P, Jebakumar SPR, David L, Mette R, Summerfield H, Evans M, White C, Robertson R, Lean C, Morris S, Winter A, Faulkner S, Goorney B, Howard L, Fairley I, Stemp C, Short L, Gomez M, Young F, Roberts M, Green S, Sivakumar K, Minton J, Siminoni A, Calderwood J, Greenhough D, DeSouza C, Muthern L, Orkin C, Murphy S, Truvedi M, McLean K, Hawkins D, Higgs C, Moyes A, Antonucci S, McCormack S, Lynn W, Bevan M, Fox J, Teague A, Anderson J, Mguni S, Post F, Campbell L, Mazhude C, Russell H, Gilson R, Carrick G, Ainsworth J, Waters A, Byrne P, Johnson M, Fidler S, Kuldanek K, Mullaney S, Lawlor V, Melville R, Sukthankar A, Thorpe S, Murphy C, Wilkins E, Ahmad S, Green P, Tayal S, Ong E, Meaden J, Riddell L, Loay D, Peacock K, Blackman H, Harindra V, Saeed AM, Allen S, Natarajan U, Williams O, Lacey H, Care C, Bowman C, Herman S, Devendra SV, Wither J, Bridgwood A, Singh G, Bushby S, Kellock D, Young S, Rooney G, Snart B, Currie J, Fitzgerald M, Arumainayyagam J, Chandramani S. A highly virulent variant of HIV-1 circulating in the Netherlands. Science 2022; 375:540-545. [PMID: 35113714 DOI: 10.1126/science.abk1688] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.
Collapse
Affiliation(s)
- Chris Wymant
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | | | - François Blanquart
- Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, PSL Research University, Paris, France.,IAME, UMR 1137, INSERM, Université de Paris, Paris, France
| | - Luca Ferretti
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Astrid Gall
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
| | - Matthew Hall
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Tanya Golubchik
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Margreet Bakker
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Swee Hoe Ong
- Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK
| | - Lele Zhao
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - David Bonsall
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Mariateresa de Cesare
- Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - George MacIntyre-Cockett
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Lucie Abeler-Dörner
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Jan Albert
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.,Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
| | - Norbert Bannert
- Division for HIV and Other Retroviruses, Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany
| | - Jacques Fellay
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.,Swiss Institute of Bioinformatics, Lausanne, Switzerland.,Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - M Kate Grabowski
- Department of Pathology, John Hopkins University, Baltimore, MD, USA
| | | | - Huldrych F Günthard
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.,Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | - Pia Kivelä
- Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland
| | - Roger D Kouyos
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.,Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | | | - Laurence Meyer
- INSERM CESP U1018, Université Paris Saclay, APHP, Service de Santé Publique, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - Kholoud Porter
- Institute for Global Health, University College London, London, UK
| | - Matti Ristola
- Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland
| | | | - Ben Berkhout
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Paul Kellam
- Kymab Ltd., Cambridge, UK.,Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK
| | - Marion Cornelissen
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.,Molecular Diagnostic Unit, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Peter Reiss
- Stichting HIV Monitoring, Amsterdam, Netherlands.,Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
| | - Christophe Fraser
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Lobo LM, Masson W, Molinero G, Levalle Cobo A, Benincasa F, Wehit G, Delgado J, Losada P, Suarez F, Barbagelata L. Role of statins in patients with MINOCA. A systematic review and meta-analysis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2534] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Given the complex etiology and a limited amount of evidence, the medical treatment (including statin use) of myocardial infarction with non-obstructive coronary artery disease (MINOCA) remains uncertain. The objective of the present study was to evaluate the effect of statin therapy on major cardiovascular events (MACE) and mortality in MINOCA patients.
Methods
A systematic review and meta-analysis of time-to-event outcomes were performed from statin's studies therapy on MINOCA patients, reporting data from MACE or mortality, after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases.
The Meta-analysis Of Observational Studies (MOOSE) and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were used to check the reporting of observational studies. The quality of the included studies was assessed by two independent review authors using the Newcastle-Ottawa Scale (NOS). The summary effect of statin therapy on the endpoints were calculated. Measures of effect size were expressed as HRs, and the I2 statistic was calculated to quantify between-studies heterogeneity and inconsistency. A fixed-effects meta-analysis model and sensitivity analysis was then applied. The level of statistical significance was set at a 2-tailed alpha of 0.05.
Results
Six observational studies of statin therapy on MINOCA, involving a total of 11171 patients, were identified and considered eligible for analysis (9129 subjects received statin therapy while 2042 patients were part of the respective control arms). Quantitative analysis (5 studies were included) showed that statin use was associated with lower mortality (HR: 0.65; 95% CI: 0.56–0.75, I2: 0%). Also, the meta-analysis showed that statin therapy was associated with a lower incidence of MACE (HR: 0.78; 95% CI: 0.69–0.88, I2: 27%).
Conclusion
Our data suggest that in a population with MINOCA, the use of statin therapy results in significant reduction on MACE and mortality. These results must be confirmed in future clinical trials.
Funding Acknowledgement
Type of funding sources: None. Mortality and MACESensitivity analysis
Collapse
Affiliation(s)
- L M Lobo
- Campo de Mayo Military Hospital, Buenos Aires, Argentina
| | - W Masson
- Italian Hospital, Caba, Argentina
| | - G Molinero
- Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology, Caba, Argentina
| | - A Levalle Cobo
- Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology, Caba, Argentina
| | - F Benincasa
- Campo de Mayo Military Hospital, Buenos Aires, Argentina
| | - G Wehit
- Campo de Mayo Military Hospital, Buenos Aires, Argentina
| | - J Delgado
- Campo de Mayo Military Hospital, Buenos Aires, Argentina
| | - P Losada
- Campo de Mayo Military Hospital, Buenos Aires, Argentina
| | - F Suarez
- Campo de Mayo Military Hospital, Buenos Aires, Argentina
| | | |
Collapse
|
12
|
Abrisqueta P, González‐Barca E, Ferrà C, Ríos E, Fernández de la Mata M, Delgado J, Andreu R, Án. Hernández‐Rivas J, José Terol M, González M, Belén Vidriales M, Baltasar P, De la Serna J, Ramírez Páyer Á, Ballester C, Moreno C, García‐Marco JA, Córdoba R, Yáñez L, Casado LF, Bosch F. IBRUTINIB FOLLOWED BY OFATUMUMAB CONSOLIDATION IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): GELLC‐7 TRIAL FROM THE SPANISH GROUP OF CLL (GELLC). Hematol Oncol 2021. [DOI: 10.1002/hon.47_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Abrisqueta
- Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron, Hematology Barcelona Spain
| | - E. González‐Barca
- Instititut Catala D'Oncologia, Hospital Duran i Reynals, IDIBELL Universitat de Barcelona, Hematology Barcelona Spain
| | - C. Ferrà
- Instititut Catala D'Oncologia Hospital Germans Trias i Pujol, Hematology Barcelona Spain
| | - E. Ríos
- Hospital Nuestra Señora de Valme, Hematology Sevilla Spain
| | | | - J. Delgado
- Hospital Clínic, Hematology Barcelona Spain
| | - R. Andreu
- Hospital Universitario La Fe, Hematology Valencia Spain
| | | | - M. José Terol
- Hospital Clínico Universitario de Valencia, Hematology Valencia Spain
| | - M. González
- Hospital Universitario de Salamanca, Hematology Salamanca Spain
| | | | - P. Baltasar
- Hospital Universitario La Paz, Hematology Madrid Spain
| | - J. De la Serna
- Hospital Universitario 12 de Octubre, Hematology Madrid Spain
| | | | - C. Ballester
- Hospital Universitari Son Espases, Hematology Palma Spain
| | - C. Moreno
- Hospital de la Santa Creu i Sant Pau, Hematology Barcelona Spain
| | | | - R. Córdoba
- Fundación Jiménez Díaz, Hematology Madrid Spain
| | - L. Yáñez
- Hospital Universitario Marqués de Valdecilla, Hematology Santander Spain
| | - L. F. Casado
- Hospital Virgen de la Salud, Hematology Toledo Spain
| | - F. Bosch
- Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron, Hematology Barcelona Spain
| |
Collapse
|
13
|
Trullas-Jimeno A, Delgado J, Garcia-Ochoa B, Wang I, Sancho-Lopez A, Payares-Herrera C, Dalhus ML, Strøm BO, Egeland EJ, Enzmann H, Pignatti F. The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation. ESMO Open 2021; 6:100159. [PMID: 34023541 PMCID: PMC8165402 DOI: 10.1016/j.esmoop.2021.100159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 04/07/2021] [Accepted: 04/25/2021] [Indexed: 11/26/2022] Open
Abstract
Avapritinib is a protein kinase inhibitor designed to selectively inhibit oncogenic KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase. On 24 September 2020, a marketing authorisation valid through the European Union was issued for avapritinib as treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the PDGFRA D842V mutation. The drug was evaluated in an open-label, phase I, first-in-human, dose-escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of avapritinib in adults with unresectable or metastatic GIST. The benefit of avapritinib was observed in patients with GIST harbouring the PDGFRA D842V mutation. The overall response rate was 95% (95% confidence interval 82.3%-99.4%), with a median duration of response of 22.1 months (95% confidence interval 14.1-not estimable months). The most common adverse events were nausea, fatigue, anaemia, periorbital and face oedema, hyperbilirubinaemia, diarrhoea, vomiting, increased lacrimation, and decreased appetite. Most of the reported cognitive effects were mild memory impairment. Rarer events were cases of severe encephalopathy and intracranial or gastrointestinal bleeding. The aim of this manuscript is to summarise the scientific review of the application leading to regulatory approval in the European Union. Avapritinib is a protein kinase inhibitor designed to inhibit oncogenic KIT and PDGFRA mutants. A marketing authorisation was issued for avapritinib as treatment of patients with GIST harbouring the PDGFRA D842V mutation. The overall response rate was 95% (95% CI 82.3-99.4), with a median duration of response of 22.1 months (95% CI 14.1-NE). The most common adverse events were nausea, fatigue, anaemia, periorbital and face oedema, hyperbilirubinaemia and diarrhoea.
Collapse
Affiliation(s)
- A Trullas-Jimeno
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands
| | - J Delgado
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Department of Haematology, Hospital Clinic, Barcelona, Spain.
| | - B Garcia-Ochoa
- Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain; Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands
| | - I Wang
- Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands; Statens Legemiddelverk, Oslo, Norway
| | - A Sancho-Lopez
- Department of Clinical Pharmacology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - C Payares-Herrera
- Department of Clinical Pharmacology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | | | - B O Strøm
- Statens Legemiddelverk, Oslo, Norway
| | | | - H Enzmann
- Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
| | - F Pignatti
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands
| |
Collapse
|
14
|
Trullas A, Delgado J, Genazzani A, Mueller-Berghaus J, Migali C, Müller-Egert S, Zander H, Enzmann H, Pignatti F. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. ESMO Open 2021; 6:100145. [PMID: 33940347 PMCID: PMC8111576 DOI: 10.1016/j.esmoop.2021.100145] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 04/06/2021] [Accepted: 04/12/2021] [Indexed: 02/07/2023] Open
Abstract
On 21 January 2021, the European Commission amended the marketing authorisation granted for pembrolizumab to include the first-line treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) in adults. The recommended dose of pembrolizumab was either 200 mg every 3 weeks or 400 mg every 6 weeks by intravenous infusion. Pembrolizumab was evaluated in a phase III, open-label, multicentre, randomised trial versus standard of care (SOC: FOLFOX6/FOLFIRI alone or in combination with bevacizumab/cetuximab) as first-line treatment of locally confirmed mismatch repair-deficient or microsatellite instability-high stage IV CRC. Subjects randomised to the SOC arm had the option to crossover and receive pembrolizumab once disease progressed. Both progression-free survival (PFS) and overall survival were primary endpoints. Pembrolizumab showed a statistically significant improvement in PFS compared with SOC, with a hazard ratio of 0.60 [95% confidence interval (CI): 0.45-0.80], P = 0.0002. Median PFS was 16.5 (95% CI: 5.4-32.4) versus 8.2 (95% CI: 6.1-10.2) months for the pembrolizumab versus SOC arms, respectively. The most frequent adverse events in patients receiving pembrolizumab were diarrhoea, fatigue, pruritus, nausea, increased aspartate aminotransferase, rash, arthralgia, and hypothyroidism. Having reviewed the data submitted, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) considered that the benefit–risk balance was positive. This is the first time the CHMP has issued an opinion for a target population defined by DNA repair deficiency biomarkers. The aim of this manuscript is to summarise the scientific review of the application leading to regulatory approval in the European Union. The European Commission amended the marketing authorisation granted for pembrolizumab to include the first-line treatment of MSI-H/dMMR mCRC. Pembrolizumab showed a significant improvement in PFS compared with standard of care (HR 0.60, 95% CI: 0.45-0.80, P = 0.0002). The most frequent adverse events with pembrolizumab were diarrhoea, fatigue, pruritus, nausea, increased aspartate aminotransferase, rash, and arthralgia. This is the first time the CHMP has issued an opinion for a target population defined by DNA repair deficiency biomarkers.
Collapse
Affiliation(s)
- A Trullas
- Oncology & Haematology Office, European Medicines Agency, Amsterdam, The Netherlands
| | - J Delgado
- Oncology & Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Department of Haematology, Hospital Clinic, Barcelona, Spain.
| | - A Genazzani
- Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands; Universita del Piemonte Orientale, Novara, Italy
| | - J Mueller-Berghaus
- Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands; Paul-Ehrlich-Institute, Langen, Germany
| | - C Migali
- Agenzia Italiana del Farmaco, Rome, Italy
| | | | - H Zander
- Paul-Ehrlich-Institute, Langen, Germany
| | - H Enzmann
- Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
| | - F Pignatti
- Oncology & Haematology Office, European Medicines Agency, Amsterdam, The Netherlands
| |
Collapse
|
15
|
Abstract
Introduction During the COVID-19 pandemic, pre-existing dementia was associated with a 3x increase in risk of hospitalisation and (25.6%) of COVID-19 related deaths had dementia. However, it is unclear whether people living with dementia are at higher risk of COVID-19 due to dementia or whether there may be a biologically plausible link between dementia and COVID-19. The ApoE e4 allele is highly associated with dementia. We aimed to test the COVID-19 risk associated with dementia and the association between ApoE e4e4 allele and COVID-19 with the aim of clarifying biological vulnerability. Methods UK Biobank (England) participants baseline (2006 to 2010), plus secondary care data to 2017. Separate analysis tested dementia and ApoE genotype association with COVID-19 status (16th March-31st May 2020) or mortality (to March 31, 2020, plus incomplete deaths from April, 2020) in logistic models, adjusted for demographics and technical covariates. Results In 269,070 participants aged 65+, including 507(0.2%) hospitalized COVID-19 patients, those with pre-existing dementia were at increased risk of being hospitalized for COVID-19 (OR = 3.50 95% CI 1.93 to 6.34) and also for COVID-19 and death (OR = 7.30 95% CI 3.28–16.21). In 375,689 European-ancestry UKB participants, ApoE e4e4 homozygotes were more likely to be COVID-19 test positives (reaching genome-wide significance: OR = 2.24, 95% CI:1.72–2.93, p = 3.24 × 10–9) and of mortality with test-confirmed COVID-19 (OR = 4.29, 95% CI: 2.38–7.72, p = 1.22 × 10–6), compared to e3e3s homozygotes. The associations were little changed in subsets of participants who were free of diseases associated with ApoE e4 and COVID-19 severity. Conclusion Dementia was found to be disproportionally common in older adults who develop severe COVID-19. We have shown a plausible genetic pathway of increased COVID-19 risk with dementia, therefore suggesting that the positive association between dementia and COVID-19 is not just the result of high cases of COVID-19 in care homes.
Collapse
Affiliation(s)
- J Masoli
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Aging, University of Connecticut
| | - C L Kuo
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Aging, University of Connecticut
| | - J Atkins
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Aging, University of Connecticut
| | - L Pilling
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Aging, University of Connecticut
| | - J Delgado
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Aging, University of Connecticut
| | - G Kuchel
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Aging, University of Connecticut
| | - D Melzer
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Aging, University of Connecticut
| |
Collapse
|
16
|
Masoli J, Atkins J, Delgado J, Pilling L, Melzer D. 12 Being Non-Frail and Free From Cardiovascular Disease Reduces COVID-19 Risk in 269,164 Older UK Biobank Participants. Age Ageing 2021. [PMCID: PMC7989621 DOI: 10.1093/ageing/afab028.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Older adults are at increased risk of COVID-19, resulting in public health shielding measures for all adults over 70 in the UK. Frailty has been proposed for risk stratification in COVID-19 with limited evidence. Cardiovascular risk factors hypertension, diabetes and raised BMI have been associated with increased COVID-19 risk. We sought to test if non-frail older adults with low cardiovascular risk had reduced COVID-19, to inform targeted shielding policies. Methods Fried and Rockwood frailty were ascertained at UK Biobank baseline (2006-2010) and electronic frailty index(eFI) in primary care data to 2017*. A cardiovascular disease risk score(CRS) consisting of smoking status, LDL-cholesterol, blood pressure, BMI, fasting glucose and physical activity was estimated at baseline. Frailty (baseline and eFI; eFI alone) and CRS were tested in logistic models against COVID-19 status and COVID-19 mortality to 14th June 2020 adjusted for demographics and technical covariates. Results N=269,164 UKB participants aged ≥65 at baseline (≥75years in 2020). 13.9% of COVID-19 positive were non-frail with low baseline CRS versus 41.8% frail with moderate/high CRS. Being non-frail and having low CRS were independently associated with reduced COVID-19. The composite of non-frail with low CRS compared to frail with moderate/high CRS had significantly reduced COVID-19 risk (composite non-frail with low CRS HR 0.61; 95% CI 0.45-0.84; p=0.0023; eFI non-frail with low CRS HR 0.16; 95%CI 0.07-0.36; p value=9.9x10-6) and COVID-19 mortality (composite non-frail HR 0.28; 95% CI 0.10-0.82; pvalue=0.02; eFI non-frail 0.07; 95% CI 0.02-0.28; pvalue=0.00014). Conclusion These results show that the COVID-19 risk in non-frail older adults with low cardiovascular risk was up to 84% lower than in those who were frail with cardiovascular risk factors. This could contribute to future work on stratification of shielding risk in older adults in future COVID-19 surges. *Planned data updates prior to the conference should enable updates to 2020.
Collapse
Affiliation(s)
- J Masoli
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Ageing, University of Connecticut
| | - J Atkins
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Ageing, University of Connecticut
| | - J Delgado
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Ageing, University of Connecticut
| | - L Pilling
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Ageing, University of Connecticut
| | - D Melzer
- University of Exeter Medical School; Royal Devon and Exeter NHS Trust; Center on Ageing, University of Connecticut
| |
Collapse
|
17
|
Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, Enzmann H, Pignatti F. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. ESMO Open 2021; 6:100087. [PMID: 33735800 PMCID: PMC7988279 DOI: 10.1016/j.esmoop.2021.100087] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 02/15/2021] [Accepted: 02/16/2021] [Indexed: 12/24/2022] Open
Abstract
Entrectinib is an inhibitor of the tyrosine kinases TRKA, TRKB, TRKC [all together known as neurotrophic tyrosine receptor kinases (NTRKs)], ROS1 and anaplastic lymphoma kinase (ALK). On 31 July 2020, a conditional marketing authorisation valid through the European Union (EU) was issued for entrectinib for the treatment of adult and paediatric patients 12 years of age and older with NTRK fusion-positive solid tumours that are locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor and have no satisfactory therapy; and also for adult patients with ROS1-positive non-small-cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors. The submission was based on three open-label, multicentre, phase I studies (ALKA, STARTRK-1 and STARTRK-NG) and one phase II study (STARTRK-2). In patients with NTRK-positive solid tumours, the objective response rate (ORR) was 63.5% [95% confidence interval (CI) 51.5% to 74.4%] and the median duration of response (DOR) was 12.9 months (95% CI 9.3-not estimable). In patients with ROS1-positive NSCLC, the ORR was 67.1% (95% CI 59.25% to 74.27%) and the median DOR was 15.7 months (95% CI 13.9-28.6 months). The most frequent adverse events were dysgeusia, fatigue, dizziness, constipation, diarrhoea, nausea, increased weight, paraesthesia, increased creatinine, myalgia, peripheral oedema, vomiting, arthralgia, anaemia and increased AST. The aim of this manuscript is to summarise the scientific review of the application leading to regulatory approval of entrectinib in the EU. Entrectinib was granted a CMA for the treatment of patients older than 12 years with NTRK fusion-positive solid tumours. A CMA was also issued for the treatment of adult patients with ROS1+ NSCLC not previously treated with ROS1 inhibitors. The submission, reviewed in this paper, was based on three open-label, multicentre, phase I studies and one phase II study.
Collapse
Affiliation(s)
- J Delgado
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Department of Haematology, Hospital Clinic, Barcelona, Spain.
| | - E Pean
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands
| | - D Melchiorri
- Department of Physiology and Pharmacology, University of Rome La Sapienza, Rome, Italy
| | - C Migali
- Agenzia Italiana del Farmaco, Rome, Italy
| | - F Josephson
- Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands; Lakemedelsverket, Uppsala, Sweden
| | - H Enzmann
- Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
| | - F Pignatti
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands
| |
Collapse
|
18
|
Delgado J, Vleminckx C, Sarac S, Sosa A, Bergh J, Giuliani R, Enzmann H, Pignatti F. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. ESMO Open 2021; 6:100074. [PMID: 33647599 PMCID: PMC7920831 DOI: 10.1016/j.esmoop.2021.100074] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 02/04/2021] [Indexed: 12/24/2022] Open
Abstract
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate of trastuzumab [a monoclonal antibody against human epidermal growth factor receptor 2 (HER2)] and DM1 (an inhibitor of tubulin polymerisation). It was initially approved in the European Union for the treatment of adult patients with HER2-positive unresectable locally advanced or metastatic breast cancer (BC) who had previously received trastuzumab and taxanes. On 18 December 2019, a variation of the marketing authorisation was approved extending this use to the adjuvant therapy of adult patients with HER2-positive early BC who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy. A phase III randomised, multicentre, open-label trial compared T-DM1 with trastuzumab as adjuvant therapy in patients with HER2-positive early BC who had received preoperative chemotherapy and HER2-targeted therapy followed by surgery, with a finding of invasive residual disease in the breast and/or axillary lymph nodes. The study met its primary endpoint by showing an increased 3-year invasive disease-free survival rate in the T-DM1 arm (88.3%) compared with the trastuzumab arm (77.0%), with an unstratified hazard ratio of 0.50 (95% confidence interval: 0.39-0.64). There was a higher incidence of hepatotoxicity (37.3% versus 10.6%), thrombocytopenia (28.5% versus 2.4%), peripheral neuropathy (32.3% versus 16.9%), haemorrhage (29.2% versus 9.6%) and pulmonary toxicity (2.8% versus 0.8%) in the T-DM1 arm compared with the control arm. The aim of this manuscript was to summarise the scientific review of the application leading to regulatory approval of this additional indication in the European Union. T-DM1 was approved for the adjuvant therapy of HER2+ early BC not in pathological complete response after taxanes + anti-HER2 neoadjuvant therapy. A phase III randomised trial revealed an increased 3-year invasive disease-free survival rate in patients receiving T-DM1 compared with trastuzumab. Patients receiving T-DM1 experienced more hepatotoxicity, thrombocytopenia, neuropathy, bleeding and lung toxicity.
Collapse
Affiliation(s)
- J Delgado
- Oncology and Haematology Office, European Medicines Agency (EMA), Amsterdam, The Netherlands; Department of Haematology, Hospital Clinic, Barcelona, Spain.
| | - C Vleminckx
- Oncology and Haematology Office, European Medicines Agency (EMA), Amsterdam, The Netherlands
| | - S Sarac
- Danish Medicines Agency, Copenhagen, Denmark; Committe for Medicinal Products for Human Use (CHMP), EMA, Amsterdam, The Netherlands
| | - A Sosa
- Danish Medicines Agency, Copenhagen, Denmark
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institute and Breast Cancer Centre, Karolinska University Hospital, Stockholm, Sweden
| | - R Giuliani
- The Clatterbridge Cancer Centre, Liverpool, UK
| | - H Enzmann
- Committe for Medicinal Products for Human Use (CHMP), EMA, Amsterdam, The Netherlands; Bundesinstitut fur Arzneimittel und Medizinprodukte, Bonn, Germany
| | - F Pignatti
- Oncology and Haematology Office, European Medicines Agency (EMA), Amsterdam, The Netherlands
| |
Collapse
|
19
|
Delgado J, Cepeda JM, Llorens P, Jacob J, Comín J, Montero M, Miró Ò, López de Sá E, Manzano L, Martín-Sánchez FJ, Formiga F, Masip J, Pérez-Calvo JI, Herrero-Puente P, Manito N. Consensus on improving the comprehensive care of patients with acute heart failure. Rev Clin Esp 2021; 221:163-168. [PMID: 33998466 DOI: 10.1016/j.rceng.2020.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Accepted: 12/04/2020] [Indexed: 10/22/2022]
Abstract
The latest acute heart failure (AHF) consensus document from the Spanish Society of Cardiology (SEC, for its initials in Spanish), Spanish Society of Internal Medicine (SEMI), and Spanish Society of Emergency Medicine (SEMES) was published in 2015, which made an update covering the main novelties regarding AHF from the last few years necessary. These include publication of updated European guidelines on HF in 2016, new studies on the pharmacological treatment of patients during hospitalization, and other recent developments regarding AHF such as early treatment, intermittent treatment, advanced HF, and refractory congestion. This consensus document was drafted with the aim of updating all aspects related to AHF and to create a document that comprehensively describes the diagnosis, treatment, and management of this disease.
Collapse
Affiliation(s)
- J Delgado
- Servicio de Cardiología, Hospital 12 de Octubre, Facultad de Medicina UCM, CIBERCV, Madrid, Spain.
| | - J M Cepeda
- Servicio de Medicina Interna, Hospital Vega Baja, Orihuela (Alicante), Spain
| | - P Llorens
- Servicio de Urgencias, Corta Estancia y Hospitalización a Domicilio, Hospital General de Alicante; ISABIAL Alicante; Universitat Miguel Hernández, Elche (Alicante), Spain
| | - J Jacob
- Servicio de Urgencias, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain
| | - J Comín
- Servicio de Cardiología, Hospital del Mar (IMAS), Barcelona, Spain
| | - M Montero
- IMIBIC, Servicio de Medicina Interna, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - Ò Miró
- Área de Urgencias, Hospital Clínic de Barcelona; Grupo de Investigación Urgencias: Procesos y Patologías, IDIBAPS; Universitat de Barcelona, Barcelona, Spain
| | - E López de Sá
- Unidad de Cuidados Agudos Cardiológicos, Hospital Universitario La Paz, Madrid, Spain
| | - L Manzano
- Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - F J Martín-Sánchez
- Servicio de Urgencias, Hospital Clínico San Carlos; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC); Universidad Complutense, Madrid, Spain
| | - F Formiga
- Servicio de Medicina Interna, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain
| | - J Masip
- Unidad de Cuidados Intensivos, Hospital Sant Joan Despí Moisès Broggi, Consorci Sanitari Integral, Universidad de Barcelona, Sant Joan Despí (Barcelona), Spain
| | - J I Pérez-Calvo
- Servicio de Medicina Interna, Hospital Central Universitario Lozano Blesa, Zaragoza, Spain
| | - P Herrero-Puente
- Servicio de Urgencias, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - N Manito
- Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain
| | | |
Collapse
|
20
|
Moretto S, Pino Andrades F, Delgado J, Fontana C, Fabris D, Nebbia G, Turcato M, Brunelli D, Pancheri L, Quaranta A. UAV prototype for localization and identification of radioactive contamination and emitters. EPJ Web Conf 2021. [DOI: 10.1051/epjconf/202125308001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The Dragon (Drone for RAdiation detection of Gammas and Neutrons) prototype aims at designing and developing an unmanned aerial vehicle (UAV) equipped with a detection system able to identify radioactive materials, spread over an area or located in a specific position. The system is focused on the localization of the unknown emitter and its subsequently identification.
The proposed prototype is made up of two easily interchangeable detection systems, one will be used as a counter while the second will be aimed to perform goodresolution gamma spectroscopy. Both solutions have neutron gamma discrimination capability in order to be suitable for special nuclear materials (SNM) detection in gamma contamination background.
The data acquisition module is made up of a compact digitizer board (RedPitaya, sampling rate of 125 MHz and 14 bits of resolution.), a mini computer (Raspberry, for example). This combination allows to install an embedded operating system (e.g. Linux) that can run the necessary software for the Data Acquisition (DAQ), like the ABCD distributed DAQ.
Our contribution will be aimed to show a comprehensive characterization of the two detection systems, a medium size CLLB scintillation detector, and a large plastic scintillator, EJ-276, in order to assess their potential use in a UAV-based radiation monitoring system.
Collapse
|
21
|
Araujo-Fernandez I, Delgado J, Moscetti L, Sarac SB, Zander H, Mueller-Egert S, Dunder K, Pean E, Bergmann L, Enzmann H, Pignatti F. The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. ESMO Open 2020; 6:100008. [PMID: 33399074 PMCID: PMC7910722 DOI: 10.1016/j.esmoop.2020.100008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 11/12/2020] [Accepted: 11/14/2020] [Indexed: 01/05/2023] Open
Abstract
Immune checkpoint inhibitors have revolutionised cancer therapeutics. Translational research evaluating the role of biomarkers is essential to identify the ideal target population for these drugs. From a regulatory perspective, the identification of biomarkers and diagnostic assays is strongly encouraged by the European Medicines Agency (EMA). The aim of this article is to analyse the role of programmed death-ligand 1 (PD-L1) expression as a predictive biomarker in relation to the data submitted for the initial assessment of atezolizumab, a monoclonal antibody targeting human PD-L1. On 20 July 2017, atezolizumab was granted a marketing authorisation valid throughout the European Union (EU) for adult patients with (i) locally advanced or metastatic non-small-cell lung cancer (NSCLC) after chemotherapy and (ii) locally advanced or metastatic urothelial carcinoma (UC) after chemotherapy or cisplatin-ineligibility. Initially, these indications were not restricted by the level of PD-L1 expression, but preliminary data from an ongoing phase III trial in patients with UC led to a restriction in the UC indication to cisplatin-ineligible patients whose tumours have ≥5% PD-L1 expression. Still, the role of PD-L1 expression as predictive biomarker for atezolizumab therapy remains inconclusive and further research is needed. Data in this paper came from the scientific review leading to the initial regulatory approval of atezolizumab in the EU and its complementary application for indication (EMEA/H/C/004143/II/0010). The full scientific assessment report and product information are available on the EMA website (www.ema.europa.eu).
Collapse
Affiliation(s)
- I Araujo-Fernandez
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Agence Nationale de Sécurité du Médicament et des Produits de Santé, Saint-Denis, France
| | - J Delgado
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Department of Haematology, Hospital Clinic, Barcelona, Spain.
| | - L Moscetti
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Department of Oncology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
| | - S B Sarac
- Danish Medicines Agency, Copenhagen, Denmark; Committee for Medicinal Products for Human Use, EMA, Amsterdam, The Netherlands
| | - H Zander
- Paul Ehrlich Institut, Langen, Germany
| | | | - K Dunder
- Committee for Medicinal Products for Human Use, EMA, Amsterdam, The Netherlands; Lakemedelsverket, Uppsala, Sweden
| | - E Pean
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands
| | - L Bergmann
- Universitatsklinikum Frankfurt, Frankfurt, Germany
| | - H Enzmann
- Committee for Medicinal Products for Human Use, EMA, Amsterdam, The Netherlands; Bundesinstitut fur Arzneimittel und Medizinprodukte, Bonn, Germany
| | - F Pignatti
- Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands
| |
Collapse
|
22
|
Delgado J, Dávila IJ, Domínguez-Ortega J. Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement. J Investig Allergol Clin Immunol 2020; 31:36-43. [PMID: 32856593 DOI: 10.18176/jiaci.0638] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND AND OBJECTIVE The definition of severe uncontrolled asthma and the best phenotype-driven management are not fully established. Objective: We aimed to reach a consensus on the definition of severe uncontrolled asthma and give recommendations on optimal management with phenotype-targeted biological therapies. METHODS A modified Delphi technique was used. A scientific committee provided statements addressing the definition of severe uncontrolled asthma and controversial issues about its treatment with biologics. The questionnaire was evaluated in 2 rounds by expert allergists. With the results, the scientific committee developed recommendations and a practical algorithm. RESULTS A panel of 27 allergists reached agreement on 27 out of the 29 items provided (93.1%). A consensus definition of severe uncontrolled asthma was agreed. Prior to initiation of therapy, it is mandatory to establish the asthma phenotype and assess the presence of clinically important allergic sensitizations. Anti-IgE, anti-IL-5, anti-IL-5 receptor, and anti-IL-13/IL-4 receptor inhibitors are suitable options for patients with allergic asthma and a blood eosinophil level >300/μL (>150/μL in patients receiving oral corticosteroids). IL-5 and anti-IL-5 receptor inhibitors are recommended for patients with an eosinophilic phenotype and can also be used for patients with severe eosinophilic allergic asthma with no or a suboptimal response to omalizumab. Dupilumab is recommended for patients with moderate-severe asthma and a TH2-high phenotype. Only physicians with experience in the treatment of severe uncontrolled asthma should initiate biological treatment. CONCLUSION We provide consensus clinical recommendations that may be useful in the management of patients with severe uncontrolled asthma.
Collapse
Affiliation(s)
- J Delgado
- Allergology Clinical Management Unit, Virgen Macarena Hospital, Seville, Spain; SEAIC Asthma Committee
| | - I J Dávila
- Allergy Service, University Hospital, Salamanca; Associate Professor, Department of Biomedical and Diagnostics Science, School of Medicine, Salamanca; SEAIC Asthma Committee
| | - J Domínguez-Ortega
- Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES); SEAIC Asthma Committee
| | | |
Collapse
|
23
|
Acciari VA, Ansoldi S, Antonelli LA, Arbet Engels A, Baack D, Babić A, Banerjee B, Barres de Almeida U, Barrio JA, Becerra González J, Bednarek W, Bellizzi L, Bernardini E, Berti A, Besenrieder J, Bhattacharyya W, Bigongiari C, Biland A, Blanch O, Bonnoli G, Bošnjak Ž, Busetto G, Carosi R, Ceribella G, Cerruti M, Chai Y, Chilingarian A, Cikota S, Colak SM, Colin U, Colombo E, Contreras JL, Cortina J, Covino S, D'Amico G, D'Elia V, Da Vela P, Dazzi F, De Angelis A, De Lotto B, Delfino M, Delgado J, Depaoli D, Di Pierro F, Di Venere L, Do Souto Espiñeira E, Dominis Prester D, Donini A, Dorner D, Doro M, Elsaesser D, Fallah Ramazani V, Fattorini A, Ferrara G, Foffano L, Fonseca MV, Font L, Fruck C, Fukami S, García López RJ, Garczarczyk M, Gasparyan S, Gaug M, Giglietto N, Giordano F, Gliwny P, Godinović N, Green D, Hadasch D, Hahn A, Herrera J, Hoang J, Hrupec D, Hütten M, Inada T, Inoue S, Ishio K, Iwamura Y, Jouvin L, Kajiwara Y, Karjalainen M, Kerszberg D, Kobayashi Y, Kubo H, Kushida J, Lamastra A, Lelas D, Leone F, Lindfors E, Lombardi S, Longo F, López M, López-Coto R, López-Oramas A, Loporchio S, Machado de Oliveira Fraga B, Maggio C, Majumdar P, Makariev M, Mallamaci M, Maneva G, Manganaro M, Mannheim K, Maraschi L, Mariotti M, Martínez M, Mazin D, Mender S, Mićanović S, Miceli D, Miener T, Minev M, Miranda JM, Mirzoyan R, Molina E, Moralejo A, Morcuende D, Moreno V, Moretti E, Munar-Adrover P, Neustroev V, Nigro C, Nilsson K, Ninci D, Nishijima K, Noda K, Nogués L, Nozaki S, Ohtani Y, Oka T, Otero-Santos J, Palatiello M, Paneque D, Paoletti R, Paredes JM, Pavletić L, Peñil P, Perennes C, Peresano M, Persic M, Prada Moroni PG, Prandini E, Puljak I, Rhode W, Ribó M, Rico J, Righi C, Rugliancich A, Saha L, Sahakyan N, Saito T, Sakurai S, Satalecka K, Schleicher B, Schmidt K, Schweizer T, Sitarek J, Šnidarić I, Sobczynska D, Spolon A, Stamerra A, Strom D, Strzys M, Suda Y, Surić T, Takahashi M, Tavecchio F, Temnikov P, Terzić T, Teshima M, Torres-Albà N, Tosti L, van Scherpenberg J, Vanzo G, Vazquez Acosta M, Ventura S, Verguilov V, Vigorito CF, Vitale V, Vovk I, Will M, Zarić D, Nava L. Bounds on Lorentz Invariance Violation from MAGIC Observation of GRB 190114C. Phys Rev Lett 2020; 125:021301. [PMID: 32701326 DOI: 10.1103/physrevlett.125.021301] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 04/20/2020] [Accepted: 06/04/2020] [Indexed: 06/11/2023]
Abstract
On January 14, 2019, the Major Atmospheric Gamma Imaging Cherenkov telescopes detected GRB 190114C above 0.2 TeV, recording the most energetic photons ever observed from a gamma-ray burst. We use this unique observation to probe an energy dependence of the speed of light in vacuo for photons as predicted by several quantum gravity models. Based on a set of assumptions on the possible intrinsic spectral and temporal evolution, we obtain competitive lower limits on the quadratic leading order of speed of light modification.
Collapse
Affiliation(s)
- V A Acciari
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - S Ansoldi
- Università di Udine, and INFN Trieste, I-33100 Udine, Italy
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - L A Antonelli
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | | | - D Baack
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - A Babić
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - B Banerjee
- Saha Institute of Nuclear Physics, HBNI, 1/AF Bidhannagar, Salt Lake, Sector-1, Kolkata 700064, India
| | - U Barres de Almeida
- Centro Brasileiro de Pesquisas Fsicas (CBPF), 22290-180 URCA, Rio de Janeiro (RJ), Brasil
| | - J A Barrio
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - J Becerra González
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - W Bednarek
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - L Bellizzi
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - E Bernardini
- Deutsches Elektronen-Synchrotron (DESY), D-15738 Zeuthen, Germany
- Università di Padova and INFN, I-35131 Padova, Italy
| | - A Berti
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | - J Besenrieder
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - W Bhattacharyya
- Deutsches Elektronen-Synchrotron (DESY), D-15738 Zeuthen, Germany
| | - C Bigongiari
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - A Biland
- ETH Zurich, CH-8093 Zurich, Switzerland
| | - O Blanch
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - G Bonnoli
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - Ž Bošnjak
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - G Busetto
- Università di Padova and INFN, I-35131 Padova, Italy
| | - R Carosi
- Università di Pisa, and INFN Pisa, I-56126 Pisa, Italy
| | - G Ceribella
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - M Cerruti
- Universitat de Barcelona, ICCUB, IEEC-UB, E-08028 Barcelona, Spain
| | - Y Chai
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - A Chilingarian
- The Armenian Consortium: ICRANet-Armenia at NAS RA, A. Alikhanyan National Laboratory
| | - S Cikota
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - S M Colak
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - U Colin
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - E Colombo
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - J L Contreras
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - J Cortina
- Centro de Investigaciones Energticas, Medioambientales y Tecnolgicas, E-28040 Madrid, Spain
| | - S Covino
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - G D'Amico
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - V D'Elia
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - P Da Vela
- Università di Pisa, and INFN Pisa, I-56126 Pisa, Italy
| | - F Dazzi
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - A De Angelis
- Università di Padova and INFN, I-35131 Padova, Italy
| | - B De Lotto
- Università di Udine, and INFN Trieste, I-33100 Udine, Italy
| | - M Delfino
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - J Delgado
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - D Depaoli
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | - F Di Pierro
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | - L Di Venere
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | - E Do Souto Espiñeira
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - D Dominis Prester
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - A Donini
- Università di Udine, and INFN Trieste, I-33100 Udine, Italy
| | - D Dorner
- Universität Würzburg, D-97074 Würzburg, Germany
| | - M Doro
- Università di Padova and INFN, I-35131 Padova, Italy
| | - D Elsaesser
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - V Fallah Ramazani
- Finnish MAGIC Consortium: Finnish Centre of Astronomy with ESO (FINCA), University of Turku, FI-20014 Turku, Finland; Astronomy Research Unit, University of Oulu, FI-90014 Oulu, Finland
| | - A Fattorini
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - G Ferrara
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - L Foffano
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M V Fonseca
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - L Font
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - C Fruck
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - S Fukami
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - R J García López
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - M Garczarczyk
- Deutsches Elektronen-Synchrotron (DESY), D-15738 Zeuthen, Germany
| | - S Gasparyan
- The Armenian Consortium: ICRANet-Armenia at NAS RA, A. Alikhanyan National Laboratory
| | - M Gaug
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - N Giglietto
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | - F Giordano
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | - P Gliwny
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - N Godinović
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - D Green
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - D Hadasch
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - A Hahn
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - J Herrera
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - J Hoang
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - D Hrupec
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - M Hütten
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - T Inada
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - S Inoue
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - K Ishio
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - Y Iwamura
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - L Jouvin
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - Y Kajiwara
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - M Karjalainen
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - D Kerszberg
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - Y Kobayashi
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - H Kubo
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - J Kushida
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - A Lamastra
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - D Lelas
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - F Leone
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - E Lindfors
- Finnish MAGIC Consortium: Finnish Centre of Astronomy with ESO (FINCA), University of Turku, FI-20014 Turku, Finland; Astronomy Research Unit, University of Oulu, FI-90014 Oulu, Finland
| | - S Lombardi
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - F Longo
- Università di Udine, and INFN Trieste, I-33100 Udine, Italy
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - M López
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - R López-Coto
- Università di Padova and INFN, I-35131 Padova, Italy
| | - A López-Oramas
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - S Loporchio
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | | | - C Maggio
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - P Majumdar
- Saha Institute of Nuclear Physics, HBNI, 1/AF Bidhannagar, Salt Lake, Sector-1, Kolkata 700064, India
| | - M Makariev
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - M Mallamaci
- Università di Padova and INFN, I-35131 Padova, Italy
| | - G Maneva
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - M Manganaro
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - K Mannheim
- Universität Würzburg, D-97074 Würzburg, Germany
| | - L Maraschi
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - M Mariotti
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M Martínez
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - D Mazin
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - S Mender
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - S Mićanović
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - D Miceli
- Università di Udine, and INFN Trieste, I-33100 Udine, Italy
| | - T Miener
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - M Minev
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - J M Miranda
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - R Mirzoyan
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - E Molina
- Universitat de Barcelona, ICCUB, IEEC-UB, E-08028 Barcelona, Spain
| | - A Moralejo
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - D Morcuende
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - V Moreno
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - E Moretti
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - P Munar-Adrover
- Departament de Física, and CERES-IEEC, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - V Neustroev
- Finnish MAGIC Consortium: Finnish Centre of Astronomy with ESO (FINCA), University of Turku, FI-20014 Turku, Finland; Astronomy Research Unit, University of Oulu, FI-90014 Oulu, Finland
| | - C Nigro
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - K Nilsson
- Finnish MAGIC Consortium: Finnish Centre of Astronomy with ESO (FINCA), University of Turku, FI-20014 Turku, Finland; Astronomy Research Unit, University of Oulu, FI-90014 Oulu, Finland
| | - D Ninci
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - K Nishijima
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - K Noda
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - L Nogués
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - S Nozaki
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - Y Ohtani
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - T Oka
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - J Otero-Santos
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - M Palatiello
- Università di Udine, and INFN Trieste, I-33100 Udine, Italy
| | - D Paneque
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - R Paoletti
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - J M Paredes
- Universitat de Barcelona, ICCUB, IEEC-UB, E-08028 Barcelona, Spain
| | - L Pavletić
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - P Peñil
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - C Perennes
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M Peresano
- Università di Udine, and INFN Trieste, I-33100 Udine, Italy
| | - M Persic
- Università di Udine, and INFN Trieste, I-33100 Udine, Italy
| | | | - E Prandini
- Università di Padova and INFN, I-35131 Padova, Italy
| | - I Puljak
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - W Rhode
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - M Ribó
- Universitat de Barcelona, ICCUB, IEEC-UB, E-08028 Barcelona, Spain
| | - J Rico
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology (BIST), E-08193 Bellaterra (Barcelona), Spain
| | - C Righi
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - A Rugliancich
- Università di Pisa, and INFN Pisa, I-56126 Pisa, Italy
| | - L Saha
- IPARCOS Institute and EMFTEL Department, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - N Sahakyan
- The Armenian Consortium: ICRANet-Armenia at NAS RA, A. Alikhanyan National Laboratory
| | - T Saito
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - S Sakurai
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - K Satalecka
- Deutsches Elektronen-Synchrotron (DESY), D-15738 Zeuthen, Germany
| | | | - K Schmidt
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - T Schweizer
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - J Sitarek
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - I Šnidarić
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - D Sobczynska
- University of Lodz, Faculty of Physics and Applied Informatics, Department of Astrophysics, 90-236 Lodz, Poland
| | - A Spolon
- Università di Padova and INFN, I-35131 Padova, Italy
| | - A Stamerra
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - D Strom
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - M Strzys
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - Y Suda
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - T Surić
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - M Takahashi
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - F Tavecchio
- National Institute for Astrophysics (INAF), I-00136 Rome, Italy
| | - P Temnikov
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - T Terzić
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - M Teshima
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - N Torres-Albà
- Universitat de Barcelona, ICCUB, IEEC-UB, E-08028 Barcelona, Spain
| | - L Tosti
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | | | - G Vanzo
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - M Vazquez Acosta
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, and Universidad de La Laguna, Departamento de Astrofísica, E-38206 La Laguna, Tenerife, Spain
| | - S Ventura
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - V Verguilov
- Institute for Nuclear Research and Nuclear Energy, Bulgarian Academy of Sciences, BG-1784 Sofia, Bulgaria
| | - C F Vigorito
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | - V Vitale
- Istituto Nazionale Fisica Nucleare (INFN), 00044 Frascati (Roma) Italy
| | - I Vovk
- Japanese MAGIC Consortium: ICRR, The University of Tokyo, 277-8582 Chiba, Japan; Department of Physics, Kyoto University, 606-8502 Kyoto, Japan; Tokai University, 259-1292 Kanagawa, Japan; RIKEN, 351-0198 Saitama, Japan
| | - M Will
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - D Zarić
- Croatian Consortium: University of Rijeka, Department of Physics, 51000 Rijeka; University of Split-FESB, 21000 Split; University of Zagreb-FER, 10000 Zagreb; University of Osijek, 31000 Osijek; Rudjer Boskovic Institute, 10000 Zagreb, Croatia
| | - L Nava
- National Institute for Astrophysics (INAF), Osservatorio Astronomico di Brera, 23807 Merate, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, 34149 Trieste, Italy
- Institute for Fundamental Physics of the Universe (IFPU), 34151 Trieste, Italy
| |
Collapse
|
24
|
Martínez-Moragón E, Delgado J, Mogrovejo S, Fernández-Sánchez T, López JJ, Orenes MÁM, Montaño PP, Toro MT, Oliver BC, Torres ÁF, Delgado PG, Rodríguez TWJ, Auli BV, Yebenes JJZ, Berasategui MTA, Jiménez MF, Ruibio NHDM, Azagra MV, Fernández JAÁ, Sainz SA, González RMB, Nieves MEG, Carpio DA, Sellés NA, García CB, Lessmann AC, Carrillo DDLR, Pla JJ, Giraldo AL, Sánchez OL, Rivera CM, Olondris PM, Gall XM, Nogués EP, Coimerma FP, Carroz KP, Blanch AR, Ortún MLR, Berenguer DS, Batlles JS, Mitjà PS, Sagardía AS, Retes LS, Combas JV, Giralte XV, Zubeldia IA, Ercoreca IA, Peña MH, Pascual MMI, Michelena CJ, Castro AL, Legarreta AL, Llorente PL, Prieto JP, Lorenzo VZ, Gil LA, Muñoz JPG, Durantez MM, Miguel TP, Ahmida T, Izquierdo MIA, Olbah MA, Muñoz AA, Núñez IG, Fernández DG, Camacho AL, Pellon LF, Miguel EMM, Portal FO, Raducan I, Prats JAR, Segarra MDS, Soler FT, Naon AL, Bonilla PG, Muñoz FLG, Calderón PM, Costa LME, Aparicio MB, Pazos JMG, Paz VG, Barcala FJG, Sotes PI, Rodríguez PJM, Nieto FM, Orjales RN, Martín CS, Antelo JS, Rodríguez JT, Español SA, Nieto CS, Talaverano GS, Rodríguez MME, López JFF, Jiménez MÁL, Vílchez MJR, Palacín SC, Quintana SD, Echeverria JAN, Guardia EFDL, Jara BH, García VM, Vazquez LV, De Sus JC, Santonio J, López JAA, Campillo EA, Molina CVJMC, Venegas ADS, Martínez PB, Reinosa BB, Parra BF, García DF, Gutiérrez VS, Lobera AVRD, Alcon SL, González FC, Fernández TG, Lázaro JM, Macenlle NM, Viteri SA, Amerigo DA, Bobolea I, Aguirre MDPC, Contreras RC, Arias FC, Álvarez MC, Martínez EBDH, Campos RMD, Cano MDMG, Rodríguez LG, Tejada JAGRD, Mancebo EG, Seco EG, Torralba FG, Santana AH, Herrera PDLH, Mosquete MRH, Rodríguez PL, Ballesteros BLM, Vicente EM, Chacón BM, Fernández AM, García EM, Castillejo EO, Serrano FP, Acevedo YPA, Rojo RP, Ruiz-Rico NQ, Pinedo ÁR, Jiménez BR, Rodríguez MR, Ingelmo AR, Peña AR, González MJS, Trujillo MJT, Fuertes LV, Albelda CV, Meniz AY, Grovas RIAP, Ramírez JARA, Muñoz JMB, Manzanares MB, Martínez GDL, Núñez IG, Luna FLD, Paez AM, Tejada EOSD, Galo AP, Cornejo MPE, Esojo CS, Alemán ÁFA, Rumayor MCA, Espinosa RA, Mora RB, Lancharro FJC, Urra TG, Martín SH, Lizaldre AR, Quintas RD. Factors that determine the loss of control when reducing therapy by steps in the treatment of moderate-severe asthma in standard clinical practice: A multicentre Spanish study. Rev Clin Esp 2020. [DOI: 10.1016/j.rceng.2019.05.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Delgado J, Martinez-Moragón E, Fernández-Sánchez T. Factors Affecting the Success of Step-up Therapy in Patients With Moderate-Severe Asthma: A Real-Life Study. J Investig Allergol Clin Immunol 2019; 31:145-150. [PMID: 31833478 DOI: 10.18176/jiaci.0470] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
INTRODUCTION AND OBJECTIVE Introduction: Clinical practice guidelines recommend regular adjustment of treatment to achieve control of asthma. A step-up approach based on the degree of disease control should be followed. Objective: To perform a real-life analysis of the factors that affect the success or failure of this therapeutic strategy and of the criteria applied by clinicians when applying a step-up approach in a representative sample of patients diagnosed with moderate-severe asthma. MATERIAL AND METHODS We performed a multicenter retrospective cohort study involving 226 Spanish specialist physicians (98 allergologists, 127 pulmonologists, and 1 family physician). We included 1254 patients (787 women) diagnosed with moderate-severe asthma who underwent step-up therapy during 2016. RESULTS Step-up was successful in 44% of cases. The factors associated with success were presence of <2 comorbid conditions, lower grade of severity and therapy step before modification, absence of exacerbations during the previous year, fewer daytime/nighttime symptoms, and limitation in activities, as well as type of inhaled corticosteroid/ long-acting β₂-agonist combination after modification, lower body mass index, and higher fractional exhaled nitric oxide. An early increase in the maintenance dose once a lack of control was detected (≤3 months, >3 to ≤6 months, >6 to ≤12 months) was more likely to be successful. CONCLUSION The factors that determine whether or not this therapeutic strategy manages to control asthma are time since onset of clinical impairment, previous grade of severity, number of comorbid conditions, previous exacerbations, and frequency of symptoms.
Collapse
Affiliation(s)
- J Delgado
- Allergology Clinical Management Unit, Hospital Virgen Macarena, Sevilla, Spain
| | - E Martinez-Moragón
- Respiratory Medicine Department, Hospital Universitario Dr. Peset, Valencia, Spain
| | | |
Collapse
|
26
|
Valero A, Olaguibel J, Delgado J, Plaza V, Álvarez F, Molina J, Mascarós E, Quirce S. Dilemmas and New Paradigms in Asthma Management. J Investig Allergol Clin Immunol 2019; 29:15-23. [PMID: 30785098 DOI: 10.18176/jiaci.0345] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Asthma is one of the most common inflammatory diseases in the world. The main goal of treatment is to achieve optimal control. Although every patient is different, clinical practice guidelines can help physicians to manage the disease. However, the recommendations made by guidelines are not always identical, and the continuous release of new data on the various management strategies can mislead both patients and physicians. We aim to summarize the main controversies in management and treatment recommendations in asthma guidelines, revise the most recent scientific evidence, and pinpoint possible solutions. We do not issue new recommendations or challenge evidence-based guidelines. We concluded that more tools are necessary to achieve and measure optimal asthma control and to better assess the impact of asthma on patients' lives. Also essential is a more accurate appraisal of the short-term and long-term effectiveness and safety of asthma therapies and the possibilities of successful immunomodulation.
Collapse
Affiliation(s)
- A Valero
- Sección de Alergología, Servicio de Neumología y Alergia, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBER de Enfermedades Respiratorias (CIBERES), Spain
| | - J Olaguibel
- Unidad de Asma Grave, Servicio de Alergología, Complejo Hospitalario de Navarra, Pamplona and CIBER de Enfermedades Respiratorias (CIBERES)
| | - J Delgado
- Unidad de Gestión Clínica de Alergología, Hospital Virgen Macarena, Sevilla, Spain
| | - V Plaza
- Servei de Pneumologia i Al·lèrgia, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - F Álvarez
- Unidad de Asma, Unidad Médico-Quirúrgica de Enfermedades Respiratorias (UMQER), Hospital Universitario "Virgen del Rocio", Sevilla, Spain
| | - J Molina
- CS Francia, Dirección Asistencial Oeste, Fuenlabrada, Madrid, Spain
| | - E Mascarós
- Centro de Salud Fuente de San Luis, Departamento Hospital Dr Peset, Valencia, Spain
| | - S Quirce
- Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ) and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
27
|
Trigueros JA, Plaza V, Domínguez-Ortega J, Serrano J, Cisneros C, Padilla A, Antón Gironés M, Mosteiro M, Martínez Moragón E, Olaguíbel Rivera JM, Delgado J, García Rivero JL, Martínez Rivera C, Garrido JJ, Quirce S. Asthma, Comorbidities, and Aggravating Circumstances: The GEMA-FORUM II Task Force. J Investig Allergol Clin Immunol 2019; 30:140-143. [PMID: 31599723 DOI: 10.18176/jiaci.0460] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J A Trigueros
- Grupo de Patología Respiratoria de la Sociedad Española de Médicos Generales y de Familia (SEMG), Centro de Salud de Menasalbas, Menasalbas, Toledo, Spain
| | - V Plaza
- Comité Ejecutivo de la Guía Española para el Manejo del Asma (GEMA), Servei de Pneumologia i Al·lèrgia, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - J Domínguez-Ortega
- Servicio de Alergología, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J Serrano
- Servicio de Neumología, Hospital Comarcal d´Inca, Inca, Islas Baleares, Spain
| | - C Cisneros
- Servicio de Neumología, Hospital Universitario de La Princesa, Instituto de Investigación La Princesa Madrid, Spain
| | - A Padilla
- Unidad de Neumología, Agencia Sanitaria Costa del Sol, Marbella, Málaga, Spain
| | - M Antón Gironés
- Servicio de Alergología, Hospital Universitario del Vinalopó, Elche, Alicante, Spain
| | - M Mosteiro
- Servicio de Neumología, Hospital Álvaro Cunqueiro, EOXI de Vigo, Vigo, Spain
| | - E Martínez Moragón
- Servicio de Neumología, Hospital Universitario Dr Peset, Valencia, Spain
| | - J M Olaguíbel Rivera
- Unidad de Asma Grave, Servicio de Alergología, Complejo Hospitalario de Navarra, CIBER de enfermedades respiratorias (CIBERES), Pamplona, Spain
| | - J Delgado
- Unidad de Gestión Sanitaria de Alergología, Hospital Virgen Macarena, Sevilla, Spain
| | - J L García Rivero
- Servicio de Neumología, Hospital de Laredo, Laredo, Cantabria, Spain
| | - C Martínez Rivera
- Servicio de Neumologia, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, CIBERES, Badalona, Barcelona, Spain
| | - J J Garrido
- Sección de Neumología, Hospital de Mérida, Mérida, Badajoz, Spain
| | - S Quirce
- Servicio de Alergología, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ) and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | | |
Collapse
|
28
|
Delgado J, García E, Ribes J, García M, Fernández P. Standardized nursing care in the department of radiotherapy of a network of cancer centres. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz274.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Izquierdo-Domínguez A, Bobolea I, Doña I, Campo P, Segura C, Ortega N, González R, Delgado J, Torres MJ, Dordal MT. Statement of the Spanish Society of Allergology and Clinical Immunology on Provocation Tests With Aspirin/Nonsteroidal Anti-inflammatory Drugs. J Investig Allergol Clin Immunol 2019; 30:1-13. [PMID: 31530511 DOI: 10.18176/jiaci.0449] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used throughout the world. They are frequently involved in hypersensitivity reactions, which range from local or mild reactions to systemic and severe reactions. Consequently, it is necessary to perform an exhaustive study of patients in order to make an accurate diagnosis, search for safe procedures in the case of severe reactions, and identify alternative treatment options. Various guidelines and protocols address the management of hypersensitivity to NSAIDs, although these vary widely from country to country. The Committees of Asthma, Rhinoconjunctivitis, and Drug Allergy of the Spanish Society of Allergy and Clinical Immunology (SEAIC) propose the present position statement on available options for provocation testing with aspirin/NSAIDs. This document is the fruit of an exhaustive review of current evidence and is based on recent publications addressing the diagnosis of patients with hypersensitivity to NSAIDs and on a consensus-oriented discussion among a group of experts from the SEAIC. The main objective was to draft an easy-toread, practical guideline for health care professionals in specialist areas who assess and manage patients with suspected hypersensitivity to NSAIDs. Furthermore, indications, contraindications, and procedures for oral, bronchial, and nasal provocation tests with aspirin/NSAIDs have been updated.
Collapse
Affiliation(s)
- A Izquierdo-Domínguez
- Allergy Service, Consorci Sanitari de Terrassa, Barcelona, Spain.,Allergy Unit, Clínica Diagonal, Barcelona, Spain
| | - I Bobolea
- Allergy Section, Servei de Pneumologia i Al.lèrgia Respiratòria, Hospital Clínic, Barcelona, Spain
| | - I Doña
- Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.,Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain
| | - P Campo
- Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.,Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain
| | - C Segura
- UGC Alergología, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - N Ortega
- Allergy Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
| | - R González
- Allergy Service, Hospital Universitario de Canarias, Tenerife, Spain
| | - J Delgado
- UGC Alergología, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - M J Torres
- Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.,Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain
| | - M T Dordal
- Allergy Unit, Servei de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, Spain
| | | |
Collapse
|
30
|
Martínez-Moragón E, Delgado J, Mogrovejo S, Fernández-Sánchez T, Jesús JL, Ángel MOM, Patricia PM, Miguel TT, Begoña CO, Ángel FT, Purificación GD, Wilfox JRT, Brian VA, José ZYJ, Teresa ABM, Marta FJ, Nieves HDMR, Marta VA, Antonio ÁFJ, Sara AS, Rosa BGM, Estela GNM, Diego AC, Núria AS, Cristina BG, Astrid CL, David DLRC, Jordi JP, Alejandra LG, Olga LS, Carlos MR, Pilar MO, Xavier MG, Ester PN, Francisco PC, Karina PC, Antoni RB, Luisa ROM, Dan SB, Joan SB, Pere SM, Ana SS, Lorena SR, Joan VC, Xavier VG, Ignacio AZ, Ignacio AE, Miguel HP, Milagros IPM, Carmen JM, Adolfo LC, Amaia LL, Paula LL, Joaquina PP, Vanessa ZL, Lidia AG, Pablo GMJ, Marisa MD, Teresa PM, Tahar A, Isabel AIM, Michael AO, Aurelio AM, Ignacio GN, Diego GF, Antonio LC, Luis FP, Maria MME, Félix OP, Isabela R, Antonio RPJ, Dolores SSM, Frederic TS, Alberto LN, Pedro GB, Luis GMF, Patricia MC, Manuel ECL, Marina BA, Manuel GPJ, Vanessa GP, Francisco-Javier GB, Pilar IS, Jorge MRP, Fernando MN, Ramón NO, Carracedo SM, Juan SA, Julia TR, Santiago AE, Carlos SN, Gladis ST, Mar ERM, Fernando FLJ, Ángeles LJM, José RVM, Susana CP, Silvia DQ, Antonio NEJ, Eduardo FDLG, Belén HJ, Victoria MG, Lucía VV, Joaquín CDS, Santonio CVJ, Alfonso ALJ, Eduardo AC, María CMJ, Dolores SVA, Patricia BM, Begoña BR, Beatriz FP, Domingo FG, Virginia SG, Adolfo VRDL, Silvia LA, Francisco CG, Teresa GF, Joaquín ML, Noemí MM, Soledad AV, Darío AA, Irina B, Puerto CAMD, Remedios CC, Fernando CA, Mercedes CÁ, Belén DHME, Magdalena DCR, Mar GCMD, Leticia GR, Andrés GRDTJ, Eloina GM, Emma GS, Fernando GT, Aythamy HS, Lys HHPD, Ruth HMM, Pedro LR, Belén LMB, Ester MV, Beatriz MC, Antonio MF, Esther MG, Elena OC, Fernando PS, Yesenia PAA, Raquel PR, Natividad QRR, Ángela RP, Beatriz RJ, Mercedes RR, Ana RI, Antonio RP, José SGM, Jesús TTM, Laura VF, Concepción VA, Alexandra YM, Ismael APGR, José ARAR, Manuel BMJ, Miguel BM, Gustavo DLM, Ignacio GN, Francisco LDL, Alfonso MP, Ezequiel OSDT, Alicia PG, Manuel PEC, Carmen SE, Francisco AAÁ, Consuelo ARM, Rubén AE, Roberto BM, Javier CLF, Tamara GU, Sonia HM, Alfredo RL, Raquel DQ. Factors that determine the loss of control when reducing therapy by steps in the treatment of moderate-severe asthma in standard clinical practice: A multicentre Spanish study. Rev Clin Esp 2019; 220:86-93. [PMID: 31350049 DOI: 10.1016/j.rce.2019.05.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Revised: 05/01/2019] [Accepted: 05/06/2019] [Indexed: 10/26/2022]
Abstract
BACKGROUND Although the clinical practice guidelines recommend continuous adjustment of asthma treatment and reducing the maintenance drugs when achieving control (step-down), there are few studies of standard clinical practice aimed at collecting information on the factors that determine step-down failure. OBJECTIVE To determine the factors that determine step-down failure in standard clinical practice of patients with moderate-severe asthma controlled by a combination of inhaled glucocorticoids and long-acting beta agonists. METHODS A multicentre retrospective study included 374 patients with moderate-severe asthma controlled with inhaled glucocorticoids and long-acting beta agonists for whom the physician indicated a step-down in 2016. RESULTS The step-down failed in 41.7% of the patients. The following factors were related to failure: greater patient age (P=.006), presence of at least 2 comorbidities (P=.016), greater severity level (severe persistent vs. moderate persistent) (P<.001), greater age at diagnosis (>40 years) (P=.045), the higher the therapeutic step before (P=.003) and after the change (P<.001), the shorter the time of improvement/control prior to the change (P=.019), lower FEV1 (P=.001) and a poorer Asthma Control Test score or Asthma Control Questionnaire score before the step-down (P<.001). The logistic regression analysis showed a higher probability of step-down failure in the more elderly patients (OR, 0.983; 95% CI 0.969-0.997) and those with severe asthma compared to those with moderate asthma (OR, 0.537; 95% CI 0.292-0.985), as well as an increased probability of success if the patients had the disease controlled for more than 6 months (OR, 2.253; 95% CI 1.235-4.112). CONCLUSION In standard clinical practice conditions, step-down fails in a high percentage of patients, and the suggestion is to indicate step-down when the patient has had more than 6 months of disease control.
Collapse
Affiliation(s)
| | - J Delgado
- Unidad de Gestión Clínica de Alergología, Hospital Virgen Macarena, Sevilla, España
| | - S Mogrovejo
- Neumología, Hospital Universitario Dr. Peset, Valencia, España
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter M, Herling C, De Paoli L, Delgado J, Gentile M, Doubek M, Mauro F, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Moia R, Gerber B, Zucca E, Ghielmini M, Cavalli F, Stüssi G, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Wierda W, Montserrat E, Gaidano G, Hallek M, Rossi D. INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). Hematol Oncol 2019. [DOI: 10.1002/hon.51_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Condoluci
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - L. Terzi di Bergamo
- Experimental Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - P. Langerbeins
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - M. Hoechstetter
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - C. Herling
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - L. De Paoli
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - J. Delgado
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - M. Gentile
- Hematology; Azienda Ospedaliera (AO) of Cosenza; Cosenza Italy
| | - M. Doubek
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F.R. Mauro
- Hematology; Sapienza University; Rome Italy
| | - G. Chiodin
- Hematology; Southampton University; Southampton United Kingdom
| | - M. Mattsson
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - J. Bahlo
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - G. Cutrona
- Hematology; IRCCS Ospedale Policlinico San Martino; Genoa Italy
| | - J. Kotaskova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - C. Deambrogi
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - R. Moia
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - B. Gerber
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - E. Zucca
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Ghielmini
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Cavalli
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Stüssi
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Neri
- Hematology; University of Milan; Milan Italy
| | | | - R. Rosenquist
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - F. Forconi
- Hematology; Southampton University; Southampton United Kingdom
| | - R. Foà
- Hematology; Sapienza University; Rome Italy
| | - S. Pospisilova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F. Morabito
- Hematology; Augusta Victoria Hospital; Jerusalem Israel
| | - W.G. Wierda
- MD Anderson Cancer Center; University of Texas; Houston United States
| | - E. Montserrat
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - G. Gaidano
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - M. Hallek
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - D. Rossi
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
32
|
Plaza V, Blanco M, Delgado J, Martínez I, Zubeldía JM, Molina J. Survey of Opinion of Spanish Physicians on the Role of Eosinophils in Asthma and Other Diseases. J Investig Allergol Clin Immunol 2019; 29:456-458. [PMID: 31172950 DOI: 10.18176/jiaci.0423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- V Plaza
- Director del Comité Ejecutivo de la Guía Española para el Manejo del Asma (GEMA), Servei de Pneumologia i Allèrgia, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelo
| | - M Blanco
- Servicio de Neumología, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | - J Delgado
- Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - I Martínez
- Hospital Universitario Son Espases, Palma, Spain
| | - J M Zubeldía
- Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - J Molina
- Centro de Salud Francia, Fuenlabrada, Spain
| |
Collapse
|
33
|
Ghia P, Flinn I, Lamanna N, Montillo M, Illés Á, Etienne G, Delgado J, Kuss B, Tam C, Offner F, Bosch F, Davids M, Jäger U, Cymbalista F, Weaver D, Lustgarten S, Youssoufian H, Stilgenbauer S. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.30_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Ghia
- Division of Experimental Oncology; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele; Milan Italy
| | - I.W. Flinn
- Lymphoma Research; Sarah Cannon Research Institute; Nashville TN United States
| | - N. Lamanna
- Department of Medicine Division of Hematology/Oncology; New York Presbyterian, Columbia University Medical Center; New York NY United States
| | - M. Montillo
- Department of Haematology and Oncology; Niguarda Cancer Center, Niguarda Hospital; Milan Italy
| | - Á. Illés
- Department of Hematology; Faculty of Medicine, University of Debrecen; Debrecen Hungary
| | - G. Etienne
- Hematology Department; Institut Bergonie; Bordeaux France
| | - J. Delgado
- Department of Hematology; Hospital Clinic; Barcelona Spain
| | - B.J. Kuss
- Molecular Medicine and Pathology; Flinders Medical Centre-Flinders University; Bedford Park Australia
| | - C.S. Tam
- Division of Hematology and Oncology; Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne; Melbourne Australia
| | - F. Offner
- Hematology; University Hospital Ghent; Gent Belgium
| | - F. Bosch
- Department of Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - M.S. Davids
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - U. Jäger
- Division of Hematology and Hemostaseology; Department of Medicine I, Medical University of Vienna; Wien Austria
| | - F. Cymbalista
- Laboratoire d'hématologie; Hôpital Avicenne; Paris France
| | - D.T. Weaver
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - S. Lustgarten
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - H. Youssoufian
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - S. Stilgenbauer
- Department III of Internal Medicine; University Hospital Ulm; Ulm Germany
| |
Collapse
|
34
|
Rivas-Delgado A, Nadeu F, Enjuanes A, Magnano L, Castrejón de Anta N, Mozas P, Baumann T, Delgado J, Balagué O, Villamor N, Campo E, Giné E, López-Guillermo A. MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.1_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Rivas-Delgado
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - F. Nadeu
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Hospital Clínic; Barcelona Spain
| | - A. Enjuanes
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Hospital Clínic; Barcelona Spain
| | - L. Magnano
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | | | - P. Mozas
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - T. Baumann
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - J. Delgado
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - O. Balagué
- Department of Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - N. Villamor
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Campo
- Department of Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Giné
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | | |
Collapse
|
35
|
Flinn I, Davids M, Hillmen P, Montillo M, Delgado J, Kuss B, Tam C, Jäger U, Ghia P, Stilgenbauer S, Lustgarten S, Weaver D, Youssoufian H, Cymbalista F. AN IMPROVED BENEFIT-RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES. Hematol Oncol 2019. [DOI: 10.1002/hon.29_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- I.W. Flinn
- Lymphoma Research; Sarah Cannon Research Institute; Nashville TN United States
| | - M.S. Davids
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - P. Hillmen
- Experimental Haematology; St James's University Hospital; Leeds United Kingdom
| | - M. Montillo
- Department of Haematology and Oncology; Niguarda Cancer Center, Niguarda Hospital; Milan Italy
| | - J. Delgado
- Department of Hematology; Hospital Clinic; Barcelona Spain
| | - B.J. Kuss
- Molecular Medicine and Pathology; Flinders Medical Centre - Flinders University; Bedford Park Australia
| | - C.S. Tam
- Division of Hematology and Oncology; Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne; Melbourne Australia
| | - U. Jäger
- Division of Hematology and Hemostaseology; Department of Medicine, Medical University of Vienna; Wien Austria
| | - P. Ghia
- Università Vita-Salute San Raffaele; IRCCS Istituto Scientifico San Raffaele; Milan Italy
| | - S. Stilgenbauer
- Department III of Internal Medicine; University Hospital Ulm; Ulm Germany
| | - S. Lustgarten
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - D.T. Weaver
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - H. Youssoufian
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - F. Cymbalista
- Laboratoire d'hématologie; Hôpital Avicenne; Paris France
| |
Collapse
|
36
|
Rivas-Delgado A, Nadeu F, Enjuanes A, Magnano L, Mozas P, Osuna M, Martín S, Baumann T, Castrejón de Anta N, Balagué O, Delgado J, Villamor N, Campo E, Giné E, López-Guillermo A. GENOTYPING PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.9_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Rivas-Delgado
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - F. Nadeu
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Hospital Clínic; Barcelona Spain
| | - A. Enjuanes
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Hospital Clínic; Barcelona Spain
| | - L. Magnano
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - P. Mozas
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - M. Osuna
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - S. Martín
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - T. Baumann
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | | | - O. Balagué
- Department of Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - J. Delgado
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | - N. Villamor
- Hematopathology Unit; Department of Pathology, Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Campo
- Department of Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Giné
- Hematology Department; Hospital Clínic de Barcelona; Barcelona Spain
| | | |
Collapse
|
37
|
De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D, De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D, Kotseva K, De Backer G, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro Conde A, Cifkova R, Crowley J, Davletov K, Bacquer DD, De Smedt D, De Sutter J, Deckers J, Dilic M, Dolzhenko M, Druais H, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N, Grobbee D, Gyberg V, Hasan Ali H, Heuschmann P, Hoes A, Jankowski P, Lalic N, Lehto S, Lovic D, Maggioni A, Mancas S, Marques-Vidal P, Mellbin L, Miličić D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Ž, Rydén L, Stagmo M, Störk S, Sundvall J, Tokgözoğlu L, Tsioufis K, Vulic D, Wood D, Wood D, Kotseva K, Jennings C, Adamska A, Adamska S, Rydén L, Mellbin L, Tuomilehto J, Schnell O, Druais H, Fiorucci E, Glemot M, Larras F, Missiamenou V, Maggioni A, Taylor C, Ferreira T, Lemaitre K, Bacquer DD, De Backer G, Raman L, Sundvall J, DeSmedt D, De Sutter J, Willems A, De Pauw M, Vervaet P, Bollen J, Dekimpe E, Mommen N, Van Genechten G, Dendale P, Bouvier C, Chenu P, Huyberechts D, Persu A, Dilic M, Begic A, Durak Nalbantic A, Dzubur A, Hadzibegic N, Iglica A, Kapidjic S, Osmanagic Bico A, Resic N, Sabanovic Bajramovic N, Zvizdic F, Vulic D, Kovacevic-Preradovic T, Popovic-Pejicic S, Djekic D, Gnjatic T, Knezevic T, Kovacevic-Preradovic T, Kos L, Popovic-Pejicic S, Stanetic B, Topic G, Gotcheva N, Georgiev B, Terziev A, Vladimirov G, Angelov A, Kanazirev B, Nikolaeva S, Tonkova D, Vetkova M, Milicic D, Reiner Ž, Bosnic A, Dubravcic M, Glavina M, Mance M, Pavasovic S, Samardzic J, Batinic T, Crljenko K, Delic-Brkljacic D, Dula K, Golubic K, Klobucar I, Kordic K, Kos N, Nedic M, Olujic D, Sedinic V, Blazevic T, Pasalic A, Percic M, Sikic J, Bruthans J, Cífková R, Hašplová K, Šulc P, Wohlfahrt P, Mayer O, Cvíčela M, Filipovský J, Gelžinský J, Hronová M, Hasan-Ali H, Bakery S, Mosad E, Hamed H, Ibrahim A, Elsharef M, Kholef E, Shehata A, Youssef M, Elhefny E, Farid H, Moustafa T, Sobieh M, Kabil H, Abdelmordy A, Lehto S, Kiljander E, Kiljander P, Koukkunen H, Mustonen J, Cremer C, Frantz S, Haupt A, Hofmann U, Ludwig K, Melnyk H, Noutsias M, Karmann W, Prondzinsky R, Herdeg C, Hövelborn T, Daaboul A, Geisler T, Keller T, Sauerbrunn D, Walz-Ayed M, Ertl G, Leyh R, Störk S, Heuschmann P, Ehlert T, Klocke B, Krapp J, Ludwig T, Käs J, Starke C, Ungethüm K, Wagner M, Wiedmann S, Tsioufis K, Tolis P, Vogiatzi G, Sanidas E, Tsakalis K, Kanakakis J, Koutsoukis A, Vasileiadis K, Zarifis J, Karvounis C, Crowley J, Gibson I, Houlihan A, Kelly C, O'Donnell M, Bennati M, Cosmi F, Mariottoni B, Morganti M, Cherubini A, Di Lenarda A, Radini D, Ramani F, Francese M, Gulizia M, Pericone D, Davletov K, Aigerim K, Zholdin B, Amirov B, Assembekov B, Chernokurova E, Ibragimova F, Kodasbayev A, Markova A, Mirrakhimov E, Asanbaev A, Toktomamatov U, Tursunbaev M, Zakirov U, Abilova S, Arapova R, Bektasheva E, Esenbekova J, Neronova K, Asanbaev A, Baigaziev K, Toktomamatov U, Zakirov U, Baitova G, Zheenbekov T, Erglis A, Andrejeva T, Bajare I, Kucika G, Labuce A, Putane L, Stabulniece M, Dzerve V, Klavins E, Sime I, Badariene J, Gedvilaite L, Pečiuraite D, Sileikienė V, Skiauteryte E, Solovjova S, Sidabraite R, Briedis K, Ceponiene I, Jurenas M, Kersulis J, Martinkute G, Vaitiekiene A, Vasiljevaite K, Veisaite R, Plisienė J, Šiurkaitė V, Vaičiulis Ž, Jankowski P, Czarnecka D, Kozieł P, Podolec P, Nessler J, Gomuła P, Mirek-Bryniarska E, Bogacki P, Wiśniewski A, Pająk A, Wolfshaut-Wolak R, Bućko J, Kamiński K, Łapińska M, Paniczko M, Raczkowski A, Sawicka E, Stachurska Z, Szpakowicz M, Musiał W, Dobrzycki S, Bychowski J, Kosior D, Krzykwa A, Setny M, Kosior D, Rak A, Gąsior Z, Haberka M, Gąsior Z, Haberka M, Szostak-Janiak K, Finik M, Liszka J, Botelho A, Cachulo M, Sousa J, Pais A, Aguiar C, Durazzo A, Matos D, Gouveia R, Rodrigues G, Strong C, Guerreiro R, Aguiar J, Abreu A, Cruz M, Daniel P, Morais L, Moreira R, Rosa S, Rodrigues I, Selas M, Gaita D, Mancas S, Apostu A, Cosor O, Gaita L, Giurgiu L, Hudrea C, Maximov D, Moldovan B, Mosteoru S, Pleava R, Ionescu M, Parepa I, Pogosova N, Arutyunov A, Ausheva A, Isakova S, Karpova A, Salbieva A, Sokolova O, Vasilevsky A, Pozdnyakov Y, Antropova O, Borisova L, Osipova I, Lovic D, Aleksic M, Crnokrak B, Djokic J, Hinic S, Vukasin T, Zdravkovic M, Lalic N, Jotic A, Lalic K, Lukic L, Milicic T, Macesic M, Stanarcic Gajovic J, Stoiljkovic M, Djordjevic D, Kostic S, Tasic I, Vukovic A, Fras Z, Jug B, Juhant A, Krt A, Kugonjič U, Chipayo Gonzales D, Gómez Barrado J, Kounka Z, Marcos Gómez G, Mogollón Jiménez M, Ortiz Cortés C, Perez Espejo P, Porras Ramos Y, Colman R, Delgado J, Otero E, Pérez A, Fernández-Olmo M, Torres-LLergo J, Vasco C, Barreñada E, Botas J, Campuzano R, González Y, Rodrigo M, de Pablo C, Velasco E, Hernández S, Lozano C, González P, Castro A, Dalmau R, Hernández D, Irazusta F, Vélez A, Vindel C, Gómez-Doblas J, García Ruíz V, Gómez L, Gómez García M, Jiménez-Navarro M, Molina Ramos A, Marzal D, Martínez G, Lavado R, Vidal A, Rydén L, Boström-Nilsson V, Kjellström B, Shahim B, Smetana S, Hansen O, Stensgaard-Nake E, Deckers J, Klijn A, Mangus T, Peters R, Scholte op Reimer W, Snaterse M, Aydoğdu S, Ç Erol, Otürk S, Tulunay Kaya C, Ahmetoğlu Y, Ergene O, Akdeniz B, Çırgamış D, Akkoyun H Kültürsay S, Kayıkçıoğlu M, Çatakoğlu A, Çengel A, Koçak A, Ağırbaşlı M, Açıksarı G, Çekin M, Tokgözoğlu L, Kaya E, Koçyiğit D, Öngen Z, Özmen E, Sansoy V, Kaya A, Oktay V, Temizhan A, Ünal S, İ Yakut, Kalkan A, Bozkurt E, Kasapkara H, Dolzhenko M, Faradzh C, Hrubyak L, Konoplianyk L, Kozhuharyova N, Lobach L, Nesukai V, Nudchenko O, Simagina T, Yakovenko L, Azarenko V, Potabashny V, Bazylevych A, Bazylevych M, Kaminska K, Panchenko L, Shershnyova O, Ovrakh T, Serik S, Kolesnik T, Kosova H, Wood D, Adamska A, Adamska S, Jennings C, Kotseva K, Hoye P Atkin A, Fellowes D, Lindsay S, Atkinson C, Kranilla C, Vinod M, Beerachee Y, Bennett C, Broome M, Bwalya A, Caygill L, Dinning L, Gillespie A, Goodfellow R, Guy J, Idress T, Mills C, Morgan C, Oustance N, Singh N, Yare M, Jagoda J, Bowyer H, Christenssen V, Groves A, Jan A, Riaz A, Gill M, Sewell T, Gorog D, Baker M, De Sousa P, Mazenenga T, Porter J, Haines F, Peachey T, Taaffe J, Wells K, Ripley D, Forward H, McKie H, Pick S, Thomas H, Batin P, Exley D, Rank T, Wright J, Kardos A, Sutherland SB, Wren L, Leeson P, Barker D, Moreby B, Sawyer J, Stirrup J, Brunton M, Brodison A, Craig J, Peters S, Kaprielian R, Bucaj A, Mahay K, Oblak M, Gale C, Pye M, McGill Y, Redfearn H, Fearnley M. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285:135-146. [DOI: 10.1016/j.atherosclerosis.2019.03.014] [Citation(s) in RCA: 101] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 02/22/2019] [Accepted: 03/19/2019] [Indexed: 12/16/2022]
|
38
|
Mozas P, Magnano L, Rivas-Delgado A, Rivero A, Nadeu F, Veloza L, González-Farré B, Baumann T, Balagué O, Giné E, Delgado J, Villamor N, Campo E, López-Guillermo A. PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE. Hematol Oncol 2019. [DOI: 10.1002/hon.66_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Mozas
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - L. Magnano
- Hematopathology Unit; Pathology Department, Hospital Clínic de Barcelona; Barcelona Spain
| | | | - A. Rivero
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - F. Nadeu
- Lymphoid Malignancies; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - L. Veloza
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | | | - T. Baumann
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - O. Balagué
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Giné
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - J. Delgado
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - N. Villamor
- Hematopathology Unit; Pathology Department, Hospital Clínic de Barcelona; Barcelona Spain
| | - E. Campo
- Pathology; Hospital Clínic de Barcelona; Barcelona Spain
| | | |
Collapse
|
39
|
Urrutia I, Delgado J, Domínguez-Ortega J, Mascarós E, Pérez M, Resler G, Plaza V. Clinical Factors Associated With Overuse of Asthma Reliever Medication. J Investig Allergol Clin Immunol 2019; 30:42-48. [PMID: 30741637 DOI: 10.18176/jiaci.0387] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
OBJECTIVE Our aim was to evaluate the relationship between the clinical factors of asthma and the use of reliever medication. METHODS We performed an observational cross-sectional study in Spain. The study population comprised patients aged ≥12 years diagnosed with persistent asthma according to the criteria of the Global Initiative for Asthma and receiving maintenance treatment for at least 12 months. Use of reliever medication was classified as low use of reliever medication (LURM) (≤2 times/wk) and high use of reliever medication (HURM) (≥3 times/wk). A variety of clinical variables and patient-reported outcomes (PROs) were recorded (eg, scores on the Asthma Control Questionnaire-5 [ACQ-5] and Test of Adherence to Inhalers [TAI]). RESULTS A total of 406 patients were recruited. Mean (SD) age was 44.3 (17.9) years, and 64% were women. Reliever medication was used ≤2 times/wk in 76.1%. Bivariate analysis showed that HURM was related to smoking habit, unscheduled emergency department visits, hospital admissions, higher doses of inhaled corticosteroid, and night awakenings in the previous 4 weeks (P<.001). The multivariate analysis showed a higher risk of using reliever medication in smokers and former smokers, when the number of night awakenings increased, in cases of self-perception of partially controlled or uncontrolled asthma, or when asthma is uncontrolled according to the ACQ-5. CONCLUSIONS Our study identifies the potential of poor use of reliever medication in the last week as an alarm signal for disease-related parameters such as exacerbations, poor asthma control, and disease severity.
Collapse
Affiliation(s)
- I Urrutia
- Respiratory Department, Galdakao Hospital, OSI Barrualde-Galdakao, Biscay, Spain
| | - J Delgado
- Allergy Department, Hospital Virgen Macarena, Sevilla, Spain
| | - J Domínguez-Ortega
- Department of Allergy, Healthcare Research Institute IdiPAZ, CIBER de Enfermedades Respiratorias, CIBERES, Hospital Universitario La Paz, Madrid, Spain
| | - E Mascarós
- Medicina de Familia y Comunitaria, Centro de Salud Fuente de San Luis, Valencia, Spain, Spain
| | - M Pérez
- Medical Department AstraZeneca, Barcelona, Spain
| | - G Resler
- Medical Department AstraZeneca, Barcelona, Spain
| | - V Plaza
- Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d´Investigació Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain
| | | |
Collapse
|
40
|
Juson A, Delgado J. The clinical profile of native-valve infective endocarditis in a tertiary hospital in the Philippines: a twelve-year retrospective study. Int J Infect Dis 2019. [DOI: 10.1016/j.ijid.2018.11.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
41
|
Delgado J, Fortinsky RH, Melzer D. PREDICTORS OF 17,000 EPISODES OF DELIRIUM IN PRIMARY CARE ELECTRONIC MEDICAL RECORDS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J Delgado
- University of Exeter Medical School, Exeter, England, United Kingdom
| | - R H Fortinsky
- UConn Center on Aging, University of Connecticut School of Medicine, Farmington, CT, USA
| | - D Melzer
- University of Exeter Medical School, Exeter, Devon, UK; UConn Center on Aging, University of Connecticut School of Medicine, Farmington, CT, USA
| |
Collapse
|
42
|
Valero R, Sanchez-Fructuoso A, Rodrigo E, Belmar L, Cos MA, Perez-Flores I, Delgado J, San Millan JCR. Variability of the Mammalian Target of Rapamycin Inhibitors Is Correlated With Long-Term Renal Graft Survival. Transplant Proc 2018; 51:341-343. [PMID: 30879537 DOI: 10.1016/j.transproceed.2018.08.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Accepted: 08/16/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND Many studies demonstrate the relationship between the high intrapatient variability of calcineurin inhibitor (CNI) levels and poor long-term renal graft outcome. Our objective is to analyze the intrapatient variability observed in the mammalian target of rapamycin inhibitors (mTOR-i) blood levels, to compare the variability of sirolimus (SRL) with that of everolimus (EVL) in kidney transplant patients converted to an mTOR-i, and to analyze whether the coefficient of variation (CV) was correlated with long-term graft survival. METHODS We analyzed 279 adult renal transplant patients converted to an mTOR-i. CV was calculated using at least 3 blood trough levels between 3 and 18 months postconversion. RESULTS The mean and median CV of the entire group was 25.54% and 23.7%, respectively. SRL and EVL mean CV was 23.8% and 27.1% (P = .03), respectively. The group of patients into the last tertile with CV> 28.52% presented a lower death-censored graft survival (75.26% vs. 93.01%, P < .0001) with a mean follow-up of 66.5 months. CONCLUSION The CV of mTOR-i is correlated with long-term renal graft survival, so it should be considered a prognostic factor. SRL has a lower CV than EVL in renal transplant patients converted to mTOR-i in the stable posttransplant phase.
Collapse
Affiliation(s)
- R Valero
- Nephrology Department, Valdecilla University Hospital, Santander, Spain.
| | - A Sanchez-Fructuoso
- Nephrology Department, Clinico San Carlos University Hospital, Madrid, Spain
| | - E Rodrigo
- Nephrology Department, Valdecilla University Hospital, Santander, Spain
| | - L Belmar
- Nephrology Department, Valdecilla University Hospital, Santander, Spain
| | - M A Cos
- Pharmacology Department, Valdecilla University Hospital, Santander, Spain
| | - I Perez-Flores
- Nephrology Department, Clinico San Carlos University Hospital, Madrid, Spain
| | - J Delgado
- Nephrology Department, Clinico San Carlos University Hospital, Madrid, Spain
| | - J C R San Millan
- Nephrology Department, Valdecilla University Hospital, Santander, Spain
| |
Collapse
|
43
|
Sousa R, Pinho MR, Delgado J, Pinto AR, Biscoito M, Dellinger T, Henriques P. Abundance and population structure of Plesionika narval (Fabricius, 1787) in the Northeastern Atlantic. BRAZ J BIOL 2018; 79:111-119. [PMID: 29694559 DOI: 10.1590/1519-6984.179610] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2017] [Accepted: 08/09/2017] [Indexed: 11/21/2022] Open
Abstract
Analysis of abundance and population structure of Plesionika narval was performed on data concerning 5,255 specimens obtained from 62 fishing sets carried out off the Madeira archipelago (Northeastern Atlantic) between 2004 and 2008 in a depth range from 101 to 350 m. Abundance ranged from 0.01 to 19.74 specimens-per-trap and significant differences were found between seasons, probably as a result of an increment of population in the spring during the recruitment season. The analysis of size distribution revealed that the carapace length (CL) ranged from 2.45 to 28.61 mm and that mean female size consistently exceeded that of males. Differences in mean CL were statistically significant between depth strata and seasons. Of the specimens sampled, 57.00% were males, 41.88% females and 1.42% undetermined. Sex ratio also differed significantly between seasons according to depth strata, consolidating the hypothesis of the existence of seasonal migrations related with the reproductive cycle of this species. Ovigerous females showed larger sizes and occurred all year around and remain in shallow waters in winter, summer and autumn and move to deeper waters in spring. The highest frequency of ovigerous females was recorded in summer, between 151 and 200 m deep supporting the hypothesis that spawning of this species occurs in shallow waters, especially in late summer.
Collapse
Affiliation(s)
- R Sousa
- Direção de Serviços de Investigação - DSI, Direção Regional das Pescas - DRP-RAM, Estrada da Pontinha, CP 9004-562, Funchal, Madeira, Portugal.,Observatório Oceânico da Madeira - OOM, Agência Regional para o Desenvolvimento da Investigação, Tecnologia e Inovação - ARDITI, Edifício Madeira Tecnopolo, Piso 0, CP 9020-105, Funchal, Madeira, Portugal
| | - M R Pinho
- Departamento de Oceanografia e Pescas - DOP, Universidade dos Açores - UAc, Cais de Santa Cruz, CP 9901-862, Horta, Portugal
| | - J Delgado
- Direção de Serviços de Investigação - DSI, Direção Regional das Pescas - DRP-RAM, Estrada da Pontinha, CP 9004-562, Funchal, Madeira, Portugal.,Centro Interdisciplinar de Investigação Marinha e Ambiental - CIIMAR, Rua dos Bragas 289, CP 4500-123, Porto, Portugal
| | - A R Pinto
- Direção de Serviços de Investigação - DSI, Direção Regional das Pescas - DRP-RAM, Estrada da Pontinha, CP 9004-562, Funchal, Madeira, Portugal
| | - M Biscoito
- Observatório Oceânico da Madeira - OOM, Agência Regional para o Desenvolvimento da Investigação, Tecnologia e Inovação - ARDITI, Edifício Madeira Tecnopolo, Piso 0, CP 9020-105, Funchal, Madeira, Portugal.,Museu de História Natural do Funchal - MMF, Rua da Mouraria, 31, CP 9000-047, Funchal, Madeira, Portugal.,Estação de Biologia Marinha do Funchal - EBMF, Centro de Ciências do Mar e do Ambiente, Cais do Carvão, CP 9000-107, Funchal, Madeira, Portugal
| | - T Dellinger
- Laboratório Biologia Marinha e Oceanografia, Universidade da Madeira - UMa, Estação Biologia Marinha do Funchal, Cais do Carvão, Prom. Orla Marítima, CP 9000-107, Funchal, Portugal
| | - P Henriques
- Universidade da Madeira - UMa, Campus da Penteada, CP 9000-390, Funchal, Portugal
| |
Collapse
|
44
|
Sousa R, Gouveia L, Pinto AR, Timóteo V, Delgado J, Henriques P. Weight-length relationships of six shrimp species caught off the Madeira Archipelago, Northeastern Atlantic. BRAZ J BIOL 2018; 79:133-138. [PMID: 29694561 DOI: 10.1590/1519-6984.180731] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2017] [Accepted: 08/14/2017] [Indexed: 11/22/2022] Open
Abstract
Length and weight relationships and descriptive statistics are reported for six shrimp species caught off the Madeira archipelago between 1983 and 2014 using bottom and floating traps from depths ranging from 50 to 1,300 m. The parameter b ranged between 2.36 for Plesionika ensis and 2.97 for Plesionika williamsi. All species showed a pattern of negative allometric growth. To the authors' knowledge all weight-length relationships presented herein are recorded for the first time from the Madeira area, and in the cases of Ligur ensiferus and Plesionika ensis are the first references worldwide.
Collapse
Affiliation(s)
- R Sousa
- Direção de Serviços de Investigação - DSI, Direção Regional das Pescas - DRP-RAM, Estrada da Pontinha, CP 9004-562, Funchal, Madeira, Portugal.,Observatório Oceânico da Madeira - OOM, Agência Regional para o Desenvolvimento da Investigação, Tecnologia e Inovação - ARDITI, Edifício Madeira Tecnopolo, Piso 0, CP 9020-105, Funchal, Madeira, Portugal
| | - L Gouveia
- Direção de Serviços de Investigação - DSI, Direção Regional das Pescas - DRP-RAM, Estrada da Pontinha, CP 9004-562, Funchal, Madeira, Portugal
| | - A R Pinto
- Direção de Serviços de Investigação - DSI, Direção Regional das Pescas - DRP-RAM, Estrada da Pontinha, CP 9004-562, Funchal, Madeira, Portugal
| | - V Timóteo
- Direção de Serviços de Investigação - DSI, Direção Regional das Pescas - DRP-RAM, Estrada da Pontinha, CP 9004-562, Funchal, Madeira, Portugal
| | - J Delgado
- Direção de Serviços de Investigação - DSI, Direção Regional das Pescas - DRP-RAM, Estrada da Pontinha, CP 9004-562, Funchal, Madeira, Portugal.,Centro Interdisciplinar de Investigação Marinha e Ambiental - CIIMAR, Rua dos Bragas, 289, CP 4050-123, Porto, Portugal
| | - P Henriques
- Universidade da Madeira - UMa, Campus da Penteada, CP 9000-390, Funchal, Madeira, Portugal
| |
Collapse
|
45
|
Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia 2018; 32:645-653. [PMID: 28924241 PMCID: PMC5843898 DOI: 10.1038/leu.2017.291] [Citation(s) in RCA: 79] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 08/07/2017] [Accepted: 09/05/2017] [Indexed: 12/11/2022]
Abstract
Genome studies of chronic lymphocytic leukemia (CLL) have revealed the remarkable subclonal heterogeneity of the tumors, but the clinical implications of this phenomenon are not well known. We assessed the mutational status of 28 CLL driver genes by deep-targeted next-generation sequencing and copy number alterations (CNA) in 406 previously untreated patients and 48 sequential samples. We detected small subclonal mutations (0.6-25% of cells) in nearly all genes (26/28), and they were the sole alteration in 22% of the mutated cases. CNA tended to be acquired early in the evolution of the disease and remained stable, whereas the mutational heterogeneity increased in a subset of tumors. The prognostic impact of different genes was related to the size of the mutated clone. Combining mutations and CNA, we observed that the accumulation of driver alterations (mutational complexity) gradually shortened the time to first treatment independently of the clonal architecture, IGHV status and Binet stage. Conversely, the overall survival was associated with the increasing subclonal diversity of the tumors but it was related to the age of patients, IGHV and TP53 status of the tumors. In conclusion, our study reveals that both the mutational complexity and subclonal diversity influence the evolution of CLL.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
- Clonal Evolution/genetics
- DNA Copy Number Variations
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Male
- Middle Aged
- Mutation/genetics
- Neoplasm Staging
- Prognosis
- Proportional Hazards Models
- Signal Transduction
- Young Adult
Collapse
Affiliation(s)
- F Nadeu
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - G Clot
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - J Delgado
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Hematology Department, Hospital Clínic, Barcelona, Spain
| | - D Martín-García
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - T Baumann
- Hematology Department, Hospital Clínic, Barcelona, Spain
| | - I Salaverria
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - S Beà
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - M Pinyol
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Unitat de Genòmica, IDIBAPS, Barcelona, Spain
| | - P Jares
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Hematology Department, Hospital Clínic, Barcelona, Spain
| | - A Navarro
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | | | - M Aymerich
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Hematology Department, Hospital Clínic, Barcelona, Spain
| | - M Rozman
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Hematology Department, Hospital Clínic, Barcelona, Spain
| | - N Villamor
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Hematology Department, Hospital Clínic, Barcelona, Spain
| | - D Colomer
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Hematology Department, Hospital Clínic, Barcelona, Spain
| | - M González
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Biología Molecular e Histocompatibilidad, Hospital Universitario, Salamanca, Spain
| | - M Alcoceba
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Biología Molecular e Histocompatibilidad, Hospital Universitario, Salamanca, Spain
| | - M J Terol
- Unidad de Hematología, Hospital Clínico Universitario, Valencia, Spain
| | - B Navarro
- Unidad de Hematología, Hospital Clínico Universitario, Valencia, Spain
| | - E Colado
- Servicio de Hematología y Hemoterapia, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - ÁR Payer
- Servicio de Hematología y Hemoterapia, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - X S Puente
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain
| | - C López-Otín
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain
| | - A López-Guillermo
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Hematology Department, Hospital Clínic, Barcelona, Spain
- Medical School, Universitat de Barcelona, Barcelona, Spain
| | - A Enjuanes
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Unitat de Genòmica, IDIBAPS, Barcelona, Spain
| | - E Campo
- Lymphoid Neoplasms Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Tumores Hematológicos, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Hematology Department, Hospital Clínic, Barcelona, Spain
- Medical School, Universitat de Barcelona, Barcelona, Spain
| |
Collapse
|
46
|
Magnano L, Balagué O, Dlouhy I, Rovira J, Karube K, Pinyol M, Rivas-Delgado A, Costa D, Martínez-Trillos A, González-Farre B, Martínez-Pozo A, Giné E, Colomer D, Delgado J, Villamor N, Campo E, López-Guillermo A. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. Ann Oncol 2017; 28:2799-2805. [PMID: 29045517 DOI: 10.1093/annonc/mdx407] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Abstract
BACKGROUND The co-existence at diagnosis of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) components (FL/DLBCL) has been considered a transformed lymphoma and accordingly treated although clinicobiological information on these patients is scarce. The aim of this study was to analyze the initial features and outcome of FL/DLBCL patients in the rituximab era. PATIENTS AND METHODS All patients consecutively diagnosed at a single institution with FL/DLBCL (n = 40), as well as those with pure FL (n = 328) or de novo DLBCL (n = 510) as controls. RESULTS The proportion of the DLBCL component was highly variable (median 50%). In 29 FL/DLBCL cases analyzed, the cell of origin was GCB in 86%, ABC in 10% and unclassifiable in 4%. NOTCH1-2 was mutated in 10% of these cases. The proportion of DLBCL component did not impact on overall survival (OS). Regarding initial characteristics, patients with FL/DLBCL were closer to FL in terms of primary nodal origin, good performance status and advanced stage, whereas the other features were intermediate between FL and DLBCL. FL/DLBCL patients were treated as DLBCL with no further intensification. Complete response and primary refractory rates were 65% and 20%, respectively, with these figures being similar to DLBCL and worse than FL. Progression-free survival and OS were intermediate between FL and DLBCL (5-year OS: 85%, 73% and 63% for FL, FL/DLBCL and DLBCL, respectively). FL/DLBCL histology did not reach independent prognostic value for OS in the multivariate analyses. CONCLUSIONS The outcome of FL/DLBCL patients is not worse than that of de novo DLBCL. These cases should be treated with immunochemotherapy as DLBCL, but intensification with ASCT may not be necessary. The biological insights of FL/DLBCL warrants further genetic and molecular studies.
Collapse
MESH Headings
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Case-Control Studies
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Follicular/complications
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/mortality
- Lymphoma, Follicular/pathology
- Lymphoma, Large B-Cell, Diffuse/complications
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Neoplasm Recurrence, Local/complications
- Neoplasm Recurrence, Local/drug therapy
- Neoplasm Recurrence, Local/mortality
- Neoplasm Recurrence, Local/pathology
- Prognosis
- Survival Rate
Collapse
Affiliation(s)
- L Magnano
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - O Balagué
- CIBERONC, Barcelona;; Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - I Dlouhy
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - J Rovira
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - K Karube
- Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus;; Faculty of Medicine, University of the Ryukyus, Japan
| | - M Pinyol
- CIBERONC, Barcelona;; Genomics Unit, IDIBAPS, Barcelona, Spain
| | - A Rivas-Delgado
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - D Costa
- Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - A Martínez-Trillos
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - B González-Farre
- CIBERONC, Barcelona;; Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - A Martínez-Pozo
- CIBERONC, Barcelona;; Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - E Giné
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - D Colomer
- Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - J Delgado
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona
| | - N Villamor
- Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - E Campo
- Hematopathology Unit, Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona;; CIBERONC, Barcelona
| | - A López-Guillermo
- Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;; CIBERONC, Barcelona;.
| |
Collapse
|
47
|
Valero A, Quirce S, Dávila I, Delgado J, Domínguez-Ortega J. Allergic respiratory disease: Different allergens, different symptoms. Allergy 2017; 72:1306-1316. [PMID: 28208220 DOI: 10.1111/all.13141] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND Spanish population is rather homogeneous in its genetic and sociocultural characteristics, but allergen sensitization shows wide geographical variations. We aimed at assessing whether sensitization to different allergens in the diverse geographical areas induced different clinical and quality-of-life characteristics in adult patients with a first-time diagnosis of rhinitis and/or asthma. METHODS Two sequential, identically designed studies were carried out to evaluate such associations (PERFILAR I and II). PERFILAR II was an extension of PERFILAR I with additional allergens being included. Both phases were epidemiological, descriptive, cross-sectional, nonintervention multicenter studies. Participants were required to have lived for at least the last 2 years in the geographical zone. Asthma control assessment was based on ACQ-5. Health-related quality of life was evaluated with validated scales for rhinitis (ESPRINT-15) and asthma (Mini-AQLQ). Skin prick tests were used to identify sensitization to involved allergens. RESULTS A total of 301 physicians recruited 2711 patients for PERFILAR I+II. Sensitization to allergens was significantly different in patients with rhinitis with/without asthma. Seasonal allergens were associated with rhinitis, a longer time to asthma development, and more severe and commonly intermittent rhinitis. HDM were associated with more common rhinitis, and Alternaria was associated with asthma. The study confirms an association of geographical areas with relevant allergens and allergic clinical picture. CONCLUSION Different types of aeroallergens and specific sensitization profiles are associated with different allergic clinical pictures (rhinitis with/without asthma), different clinical symptoms, and different levels of severity. This could have implications to predict later clinical course and to select appropriate management approaches.
Collapse
Affiliation(s)
- A. Valero
- Pneumology and Allergy Department; Clinical and Experimental Respiratory Immunoallergy; IDIBAPS; CIBERES; Hospital Clinic; Barcelona Spain
| | - S. Quirce
- Department of Allergy; Healthcare Research Institute IdiPAZ; CIBER de Enfermedades Respiratorias; CIBERES; Hospital Universitario La Paz; Madrid Spain
| | - I. Dávila
- Immunoallergy Department; IBSAL-Hospital Universitario de Salamanca; Salamanca Spain
| | - J. Delgado
- Allergy Department; Hospital Virgen Macarena; Sevilla Spain
| | - J. Domínguez-Ortega
- Department of Allergy; Healthcare Research Institute IdiPAZ; CIBER de Enfermedades Respiratorias; CIBERES; Hospital Universitario La Paz; Madrid Spain
| |
Collapse
|
48
|
Alvarez-Garcia J, Garcia-Osuna A, Ferrero-Gregori A, Vives-Borras M, Perez-Calleja R, Puig T, Rivera M, Pascual-Figal D, Alonso-Pulpon L, Fernandez-Aviles F, Delgado J, Gonzalez-Juanatey J, Worner F, Ordonez-Llanos J, Cinca J. P5287Time course of a set of biomarkers during compensation of an acute heart failure episode. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J. Alvarez-Garcia
- Hospital de la Santa Creu i Sant Pau, IIb-Sant Pau, CIBERCV, Universitat A, Cardiology, Barcelona, Spain
| | - A. Garcia-Osuna
- Hospital de la Santa Creu i Sant Pau, Biochemistry, Barcelona, Spain
| | - A. Ferrero-Gregori
- Hospital de la Santa Creu i Sant Pau, IIb-Sant Pau, CIBERCV, Universitat A, Cardiology, Barcelona, Spain
| | - M. Vives-Borras
- Hospital de la Santa Creu i Sant Pau, IIb-Sant Pau, CIBERCV, Universitat A, Cardiology, Barcelona, Spain
| | - R. Perez-Calleja
- Hospital de la Santa Creu i Sant Pau, Biochemistry, Barcelona, Spain
| | - T. Puig
- Hospital de la Santa Creu i Sant Pau, IIb-Sant Pau, CIBERCV, Universitat A, Cardiology, Barcelona, Spain
| | - M. Rivera
- University Hospital La Fe, Cardiology, Valencia, Spain
| | - D. Pascual-Figal
- Hospital Clínico Univeristario Virgen de la Arrixaca, Cardiology, Murcia, Spain
| | - L. Alonso-Pulpon
- University Hospital Puerta de Hierro Majadahonda, Cardiology, Madrid, Spain
| | | | - J. Delgado
- University Hospital 12 de Octubre, Cardiology, Madrid, Spain
| | - J.R. Gonzalez-Juanatey
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | - F. Worner
- Hospital Arnau de Vilanova, Cardiology, Lleida, Spain
| | - J. Ordonez-Llanos
- Hospital de la Santa Creu i Sant Pau, Biochemistry, Barcelona, Spain
| | - J. Cinca
- Hospital de la Santa Creu i Sant Pau, IIb-Sant Pau, CIBERCV, Universitat A, Cardiology, Barcelona, Spain
| | | |
Collapse
|
49
|
Sole Gonzalez E, Ferrero-Gregori A, Puig T, Alvarez-Garcia J, Vives-Borras M, Vazquez R, Delgado J, Pascual-Figal D, Gonzalez-Juanatey J, Bardaji A, Bascompte R, Roig E, Cinca J. P5256Role of pathophysiological cardiac substrate on prognosis of ambulatory patients with chronic heart failure. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- E. Sole Gonzalez
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | - A. Ferrero-Gregori
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | - T. Puig
- Hospital de la Santa Creu i Sant Pau, Epidemiology and Public Health Department, Barcelona, Spain
| | - J. Alvarez-Garcia
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | - M. Vives-Borras
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | - R. Vazquez
- University Hospital Puerta del Mar, Cardiology Department, Cadiz, Spain
| | - J. Delgado
- University Hospital 12 de Octubre, Cardiology Department, Madrid, Spain
| | - D. Pascual-Figal
- Hospital Clínico Univeristario Virgen de la Arrixaca, Cardiology Department, Murcia, Spain
| | - J.R. Gonzalez-Juanatey
- University Hospital of Santiago de Compostela, Cardiology Department, Santiago de Compostela, Spain
| | - A. Bardaji
- Hospital Universitario Joan XXIII, Cardiology Department, Tarragona, Spain
| | - R. Bascompte
- Hospital Arnau de Vilanova, Cardiology Department, Lleida, Spain
| | - E. Roig
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | - J. Cinca
- Hospital de la Santa Creu i Sant Pau, Cardiology Department, Barcelona, Spain
| | | |
Collapse
|
50
|
Dominguez-Ortega J, Delgado J, Blanco C, Prieto L, Arroabarren E, Cimarra M, Henriquez-Santana A, Iglesias-Souto J, Vega-Chicote JM, Tabar AI. Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence. J Investig Allergol Clin Immunol 2017; 27:1-35. [PMID: 28603089 DOI: 10.18176/jiaci.0149] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients.
Collapse
Affiliation(s)
- J Dominguez-Ortega
- Servicio de Alergología, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), CIBER de Enfermedades Respiratorias, CIBERES, Madrid, Spain
| | - J Delgado
- Unidad de Gestión Clínica de Alergología, Hospital Virgen Macarena, Sevilla, Spain
| | - C Blanco
- Servicio de Alergia, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain
| | - L Prieto
- Sección de Alergología and Universidad de Valencia, Valencia, Spain
| | - E Arroabarren
- Servicio de Alergología, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - M Cimarra
- Servicio de Alergología, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - A Henriquez-Santana
- Servicio de Alergología, Hospital Universitario Infanta Elena (Valdemoro), Madrid, Spain
| | | | - J M Vega-Chicote
- Unidad de Gestión Clínica de Alergología, Hospital Regional Universitario de Málaga, Spain
| | - A I Tabar
- Servicio de Alergología, Complejo Hospitalario de Navarra, Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IdiSNA), RETIC de Asma, Reacciones adversas y Alérgicas (ARADYAL), Pamplona, Spain
| |
Collapse
|